

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR FILING APPLICATION

Under Rule 53(a), (b) & (f)

(No Filing Fee or Oath/Declaration)

(Do NOT use for Provisional or PCT Applications)

Use for Design or Utility Applications

PATENT
APPLICATION

RULE 53(f) NO DECLARATION

Assistant Commissioner of Patents

Atty. Dkt.

PM 274355

990111BT-

PAT

M#

Client Ref

and Trademarks
Washington, DC 20231

Date:

November 3, 2000

Sir:

1. This is a Request for filing a new Patent Application (☐ Design ☒ Utility) entitled:2. (Complete) Title: **PLASMIDS FROM CORYNEBACTERIUM GLUTAMICUM AND USE THEREOF**without a filing fee or Oath/Declaration but for which is enclosed the following:3. ☒ Abstract 1 page(s).4. 68 Pages of Specification (only spec. and claims); 5. ☐ Specification in non-English language6. 12 Numbered claim(s); and7. ☒ Drawings: 4 sheet(s) ☐ 1 set informal; 8. ☒ formal of size: ☒ A4 ☐ 11"DOMESTIC/INTERNATIONAL priority is claimed under 35 USC 119(e)/120/365(c) based on the following provisional, nonprovisional and/or PCT international application(s):

Application No.	Filing Date	Application No.	Filing Date
(1)		(2)	
(3)		(4)	
(5)		(6)	

10. FOREIGN priority is claimed under 35 USC 119(a)-(d)/365(b) based on filing in GERMANY

Application No.	Filing Date	Application No.	Filing Date
(1) 199 53 206.0	November 5, 1999	(2)	
(3)		(4)	
(5)		(6)	

11. 1 (No.) Certified copy (copies): ☒ attached; ☐ previously filed (date) _____
in U.S. Application No. / filed on _____12. ☐ This is a reissue of Patent No. _____13. ☐ See top first page re prior Provisional, National, International application(s) (X box only if info is there and do not complete corresponding item 14 or 15.)14. ☐ **Amend the specification** by inserting before the first line -- This is a ☐ Continuation-in-Part
☐ Divisional ☐ Continuation ☐ Substitute Application (MPEP 201.09) of:14(a) ☐ National Appn. No. / filed -- (M#)14(b) ☐ International Appn. No. PCT/ filed _____ which
designated the U.S. - -15. ☐ **Amend the specification** by inserting before the first line: --This application
claims the benefit of U.S. Provisional Application No. 60/ , filed --16. Extension to date: ☐ concurrently filed ☐ not needed ☐ previously filed

17. ☐ Prior application is assigned to

by Assignment recorded _____ Reel _____ Frame _____

18. ☐ Attached:

19. This application is made by the following named inventor(s)

(Double check instructions for accuracy.):

(1) Inventor	Andreas	TAUCH	
	First	Middle Initial	Family Name
Residence	Bielefeld	GERMANY	GERMANY
	City	State/Foreign Country	Country of Citizenship
Post Office Address	Delbrückerstrasse 15, D-33647 Bielefeld, Germany		
(include Zip Code)			

(2) Inventor	Jörn	KALINOWSKI	
	First	Middle Initial	Family Name
Residence	Bielefeld	GERMANY	GERMANY
	City	State/Foreign Country	Country of Citizenship
Post Office Address	Lenbachstrasse 19, D-33615 Bielefeld, Germany		
(include Zip Code)			

(3) Inventor	Alfred	PÜHLER	
	First	Middle Initial	Family Name
Residence	Bielefeld	GERMANY	GERMANY
	City	State/Foreign Country	Country of Citizenship
Post Office Address	Am Waldschlösschen 2, D-33739 Bielefeld, Germany		
(include Zip Code)			

(4) Inventor	Georg	THIERBACH	
	First	Middle Initial	Family Name
Residence	Bielefeld	GERMANY	GERMANY
	City	State/Foreign Country	Country of Citizenship
Post Office Address	Gunststrasse 21, D-33613 Bielefeld, Germany		
(include Zip Code)			

(5) Inventor			
	First	Middle Initial	Family Name
Residence			
	City	State/Foreign Country	Country of Citizenship
Post Office Address			
(include Zip Code)			

20. NOTE: FOR ADDITIONAL INVENTORS, check box ☐
and attach sheet with same information regarding additional inventors.


Pillsbury Madison & Sutro LLP
Intellectual Property Group

1100 New York Avenue, NW.
Ninth Floor
Washington, DC 20005-3918
Tel: (202) 861-3000
Atty/Sec: ASH/nlh

By: Atty: Ann S. Hobbs

Reg. No. 36830

Sig:



Fax: (202) 822-0944

Tel: (202) 861-3063

NOTE: File in duplicate with 2 post card receipts (PAT-103) & attachments

APPLICATION UNDER UNITED STATES PATENT LAWS

Atty. Dkt. No. PM 274355
(M#)

Invention: PLASMIDS FROM CORYNEBACTERIUM GLUTAMICUM AND USE THEREOF

Inventor (s): TAUCH, Andreas
KALINOWSKI, Jörn
PÜHLER, Alfred
THIERBACH, Georg

Pillsbury Madison & Sutro LLP
Intellectual Property Group
1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
Attorneys
Telephone: (202) 861-3000

This is a:

- ☐ Provisional Application
- ☒ Regular Utility Application
- ☐ Continuing Application
☒ The contents of the parent are incorporated by reference
- ☐ PCT National Phase Application
- ☐ Design Application
- ☐ Reissue Application
- ☐ Plant Application
- ☐ Substitute Specification
Sub. Spec Filed _____
in App. No. 1 _____
- ☐ Marked up Specification re
Sub. Spec. filed _____
In App. No. 1 _____

SPECIFICATION

**Plasmids from *Corynebacterium glutamicum* and use
thereof**

This application claims priority from German Application
5 No. DE 199 53 206.0, filed on November 5, 1999, the subject
matter of which is hereby incorporated herein by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

10 The present invention provides the novel plasmids pTET3 and
pCRY4 and the use thereof for the production of vector
plasmids.

2. Background Information

Naturally occurring plasmids and plasmid vectors produced
15 therefrom are vital to the improvement of the production
characteristics of coryneform bacteria. Constructing
plasmid vectors for this group of industrially significant
bacteria is substantially based on cryptic plasmids, which
are provided with suitable selection markers capable of
20 functioning in *Corynebacteria* or *Brevibacteria* (U.S. Pat.
No. 5,158,891 and U.S. Pat. No. 4,500,640). These plasmid
vectors may be used for cloning and amplifying genes which
are involved in the production of L-amino acids, vitamins
or nucleotides. Expression of these particular genes may
25 have a positive influence on the production of the desired
substances. Thus, for example, cloning a DNA fragment which
encodes a protein for a lysine exporter resulted in an
improvement in the fermentative production of L-lysine with
Corynebacterium glutamicum strain MH20-22B (DE-A 19548222).
30 In contrast with the known and equally industrially
significant bacterium *Escherichia coli*, only a limited
number of natural plasmids and suitable selection markers
are available for developing cloning and expression vectors

for *Corynebacteria* and *Brevibacteria*. Many plasmids known by different names prove to be identical on more detailed analysis of their genetic organisation. These plasmid isolates have thus been classed in two groups (Sonnen et al., Gene 107, 69-74 (1991)).

The pBL1 group includes the plasmids pAM286 from *Corynebacterium glutamicum* AJ11560 (EP-A 0093611), pAM330 from *Brevibacterium lactofermentum* ATCC13869 (Miwa et al., Agricultural and Biological Chemistry 48, 2901-2903 (1984)), pX18 from *Brevibacterium lactofermentum* ATCC21086 (Yeh et al, Gene 47, 301-308 (1986)) and pBL1 from *Brevibacterium lactofermentum* ATCC21798 (Santamaria et al., Journal of General Microbiology 130, 2237-2246 (1984)).

The pHM1519 group comprises plasmids pCG1 from *Corynebacterium glutamicum* ATCC31808 (U.S. Pat. No. 4,617,267), pHM1519 from *Corynebacterium glutamicum* ATCC13058 (Miwa et al., Agricultural and Biological Chemistry 48, 2901-2903 (1984)), pSR1 from *Corynebacterium glutamicum* ATCC19223 (Yoshihama et al., Journal of Bacteriology 162, 591-597 (1985)) and pRN3.1 from *Corynebacterium glutamicum* ATCC39269 (U.S. Pat. No. 4,559,308).

In addition to members of these two groups of plasmids, the cryptic plasmids pCG2 from *Corynebacterium glutamicum* ATCC31832 (U.S. Pat. No. 4,489,160) and pAG3 from *Corynebacterium melassecola* 22220 (U.S. Pat. No. 5,158,891) have also been isolated.

The only selection systems which have hitherto been available are two antibiotic resistance markers which were identified on the streptomycin/spectinomycin resistance plasmid pCG4 from *Corynebacterium glutamicum* ATCC31830 (U.S. Pat. No. 4,489,160) and on the tetracycline

resistance plasmid pAG1 from *Corynebacterium melassecola* 22243 (U.S. Pat. No. 5,158,891). Plasmid pCG4 also bears the *sulI* gene which imparts sulfamethoxazole resistance, the sequence of which gene was determined by Nesvera et al. 5 (FEMS Microbiology Letters 169, 391-395 (1998)).

If strains which produce amino acids, vitamins or nucleotides are to be rapidly investigated and improved, it is important to have plasmid vectors which are mutually compatible and are sufficiently stable.

10 It is known from the prior art that pHM1519 plasmid derivatives and pBL1 plasmid derivatives may coexist. It is furthermore known that the plasmids pGA1 and pGA2 described in U.S. Pat. No. 5,175,108 are compatible.

Plasmid vectors having high, moderate or low copy numbers 15 so that expression of the gene under consideration may be graduated are also of significance. Most known plasmids have a high copy number. Only the plasmid pGA2 described in U.S. Pat. No. 5,175,108 is known to have a low copy number.

The widely used plasmid vectors are composed of components 20 originating from the species *C. glutamicum* and components from another species of bacteria, typically *E. coli*. This method introduces foreign DNA into the species *C. glutamicum*. Functional plasmid vectors with a graduated copy number which contain only endogenous DNA and thus meet 25 the criteria of self cloning are not known in specialist circles.

SUMMARY OF THE INVENTION

Object of the invention

It is an object of the invention to provide novel plasmids 30 that are suitable for constructing plasmid vectors having

improved characteristics for coryneform bacteria which produce amino acids, vitamins and nucleotides.

Description of the invention

Amino acids, vitamins and nucleotides are used in animal
5 nutrition, in the food industry, in the pharmaceuticals
industry and in human medicine. These substances are
produced with strains of coryneform bacteria. Production
characteristics are improved by amplifying suitable genes
by means of plasmid vectors. There is accordingly general
10 interest in providing novel plasmid vectors having improved
characteristics.

The present invention provides the mutually compatible
plasmids pTET3 and pCRY4, isolated from the strain of
Corynebacterium glutamicum deposited under DSM number 5816,
15 wherein

- 1.1 plasmid pTET3 is characterised by a length of ~ 27.8
kbp and the restriction map shown in Figure 1, and an
antibiotic resistance region and
- 1.2 plasmid pCRY4 is characterised by a length of ~ 48 kbp
20 and the restriction map shown in Figure 2.

The present invention also provides composite plasmids of
pTET3 and pCRY4 capable of autonomous replication in
coryneform bacteria, said plasmids containing

- 2.1 a part or the entire quantity of the nucleotide
25 sequences
- 2.2 at least one DNA replication region derived from one
of the plasmids pTET3 or pCRY4

2.3 optionally a gene fragment which is derived from a plasmid which can multiply in *E. coli*, *B. subtilis* or *Streptomyces* and

2.4 at least one region for expressing active substance resistance, preferably from the plasmid pTET3.

The present invention also provides composite plasmids which contain at least part of the active substance resistance(s) and pGA1 and/or pGA2 from the novel plasmids according to the invention.

10 The novel plasmid pTET3, the restriction map of which is shown in Figure 1, has

1. a replication region comprising the nucleotide sequence shown in SEQ ID NO:1 and
2. an antibiotic resistance region consisting of a teta
- 15 gene imparting tetracycline resistance and an aadA gene imparting streptomycin and spectinomycin resistance, shown in SEQ ID NO:6.

The novel plasmid pCRY4, the restriction map of which is shown in Figure 2, has a replication region comprising the
20 nucleotide sequence shown in SEQ ID NO:4.

The present invention also provides the production of amino acids, vitamins and nucleotides using plasmid vectors (composite plasmids) which contain pTET3 and pCRY4 and optionally pGA1 or pGA2 nucleotide sequences.

25 *Corynebacterium glutamicum* LP-6, which was deposited as DSM5816 in the context of EP-B 0 472 869, contains the novel plasmids pTET3 and pCRY4 in addition to the plasmids pGA1 and pGA2 described therein. The storage period for DSM5816 has been extended pursuant to rule 9.1 of the
30 Budapest Treaty.

Plasmids pTET3 and pCRY4 are prepared by culturing strain LP-6 in a conventional medium, such as for example brain-heart bouillon or Luria-Bertani medium. The cells were harvested by centrifugation, treated with lysozyme and digested by the alkaline lysis method. The DNA is then purified by anion exchange chromatography on silica gel particles, precipitated with ethanol or isopropanol and then resuspended in H₂O. Complete systems for isolating plasmid DNA are commercially available as "kits". One example of such a kit is the "NucleoBond Plasmid Kit" from Clontech Laboratories GmbH. The person skilled in the art will find detailed instructions relating to the use of this kit in the manual "NucleoBond Nucleic Acid Purification Kits and Cartridges, User Manual (PT3167-1)" from Clontech Laboratories GmbH (Heidelberg, Germany, 1997). Plasmids pTET3 and pCRY4 are revealed as plasmid bands by separating the total plasmid DNA obtained in this manner by agarose gel electrophoresis and staining with ethidium bromide. DNA from the plasmid pTET3 and DNA from the plasmid pCRY4 may then be isolated from the agarose gel. To this end, the agarose gel containing the plasmid DNA is combined with a chaotropic reagent, the plasmid DNA present in the resultant solution is bound onto the surface of glass or silica gel particles and then eluted back out from this matrix. The person skilled in the art will find detailed instructions relating to this process in the manual "QIAEX II Handbook for DNA Extraction from Agarose Gels" from Qiagen GmbH (Hilden, Germany, 1997). In this manner, it is possible to prepare pTET3 DNA and pCRY4 DNA in pure form.

DNA of the plasmid to be investigated is treated with restriction enzymes individually or in combination as described by Roberts et al. (Nucleic Acids Research 27, 312-313 (1999)). The resultant DNA fragments are separated by agarose gel electrophoresis and the restriction sites

assigned. The person skilled in the art will find instructions in this connection, for example, in Rodriguez and Tait "Recombinant DNA Techniques: An Introduction" (Addison-Wesley Publishing Company, London, 1983) or in
5 "Guide to Molecular Cloning Techniques" edited by Berger and Kimmel (Methods in Enzymology, Vol. 152, Academic Press, London, 1987). In this manner, the length of the plasmid may be determined or the restriction map plotted. Plasmid pTET3 has a length of approximately 27.8 kbp and is
10 shown in Figure 1. Plasmid pCRY4 has a length of approximately 48 kbp and is shown in Figure 2.

Plasmids pTET3 and pCRY4 have a moderate or low copy number. By virtue of this property, they advantageously complement the range of known plasmids for *Corynebacterium*.
15 Instructions relating to determining copy number may be found, for example, in Miwa et al. (Agricultural and Biological Chemistry 48, 2901-2903 (1984)) and Vohradsky et al. (Electrophoresis 13, 601-612 (1993)).

In order to ensure simple handling of plasmids pTET3 and
20 pCRY4, the DNA region responsible for replication on each plasmid is determined. Known plasmid vectors of *Escherichia coli* such as for example pK18 (Pridmore, Gene 56, 309-312 (1987)), pK18mob2 (Tauch et al., Plasmid 40, 126-139 (1998)) or pCR2.1 (Invitrogen BV, Groningen, Netherlands),
25 which cannot replicate in coryneform bacteria, but the resistance gene of which is expressed, are used for this purpose. DNA from plasmids pTET3 and pCRY4 is isolated and treated with restriction enzymes. Individual DNA fragments obtained in this manner may optionally in turn be isolated.
30 The DNA of the plasmid vectors used is treated with the same restriction enzymes or such enzymes that produce compatible ends. The resultant DNA molecules are mixed and treated with T4 DNA ligase. These "cloning" techniques were

known in the prior art and are described in detail in, for example, Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)). After transforming a coryneform host, for example *Corynebacterium glutamicum*, with the ligation mixture and selecting for the resistance gene of the *E. coli* plasmid vector used, transformants are obtained. Instructions relating to the transformation of coryneform bacteria may be found, for example, in Thierbach et al. (Applied and Environmental Microbiology 29, 356-362 (1988)), in Liebl et al. (FEMS Microbiology Letters 65, 299-304 (1989)) or in Dunican et al. (Bio/Technology 7, 1067-1070 (1989)). The plasmid DNA of these transformants contains DNA segments of pTET3 or pCRY4, which impart the ability to replicate in coryneform bacteria. Examples of these are:

- plasmid pTET3-Rep, which consists of the *E. coli* plasmid pK18mob2 and the replication region of plasmid pTET3 (Figure 3), and
- plasmid pCRY4-Rep, which consists of the *E. coli* plasmid pK18mob2 and the replication region of plasmid pCRY4 (Figure 4).

The sections of DNA characterised in this manner are then in turn subcloned into usual vectors suitable for DNA sequencing. Examples of such vectors suitable for DNA sequencing are, for example, the plasmids pGEM-5zf(-) or pGEM-5zf(+) from Promega Corporation (Promega Protocols and Application Guide, Second Edition, 1991, part number Y981, Promega Corporation, Madison, WI, USA), plasmid pUC19 (Yanish-Perron et al., Gene 33, 103-119 (1985)) or plasmid pK18 (Pridmore, Gene 56, 309-312 (1987)).

DNA sequencing methods are described *inter alia* in Sanger et al. (Proceedings of the National Academy of Sciences of

the United States of America USA, 74, 5463-5467, 1977) and in Zimmermann et al. (Nucleic Acids Research 18, 1067 (1990)).

The resultant DNA sequences may then be investigated using
 5 known algorithms or sequence analysis programs, for example the "STADEN computer software package" (Molecular Biotechnology 5, 233-241 (1996)), Butler's GCG program (Methods of Biochemical Analysis 39, 74-97 (1998)), Pearson & Lipman's FASTA algorithm (Proceedings of the National
 10 Academy of Sciences USA 85, 2444-2448 (1988)) or Altschul et al.'s BLAST algorithm (Nature Genetics 6, 119-129 (1994)) and compared with the sequence entries available in publicly accessible databases. Publicly accessible nucleotide sequence databases are, for example, the
 15 European Molecular Biology Laboratory database (EMBL, Heidelberg, Germany) or the National Center for Biotechnology Information database (NCBI, Bethesda, MD, USA).

The novel DNA sequence responsible for replication of the
 20 plasmid pTET3, which sequence is provided by the present invention as SEQ ID NO:1, and which bears the repA gene responsible for replication and the parA gene responsible for stability, was obtained in this manner. The amino acid sequences of the encoded proteins were furthermore deduced
 25 from this DNA sequence. SEQ ID NO:2 shows the resultant amino acid sequence of the stabilisation protein ParA, while SEQ ID NO:3 shows the resultant amino acid sequence of the replication protein RepA of pTET3.

The novel DNA sequence responsible for replication of the
 30 plasmid pCRY4, which sequence is provided by the present invention as SEQ ID NO:4, and which bears the repA gene responsible for replication of pCRY4, was furthermore obtained in this manner. SEQ ID NO:5 shows the deduced

amino acid sequence of the replication protein RepA of plasmid pCRY4.

Few naturally occurring genes that impart resistance to antibiotics in *Corynebacterium glutamicum* are known. The
5 inventors were accordingly all the more surprised to find that plasmid pTET3 imparts resistance to the antibiotics tetracycline, streptomycin, spectinomycin and sulfamethoxazole.

In order to identify antibiotic resistance genes on new
10 plasmids, the strain to be investigated, in the present case *Corynebacterium glutamicum* LP-6, and a sensitive control strain, in the present case *Corynebacterium glutamicum* ATCC13032, are initially tested for resistance or sensitivity to various antibiotics and concentrations of
15 antibiotics. The National Committee of Clinical Laboratory Standards (NCCLS) experimental procedure is preferably used for this purpose ("Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically", fourth edition; Approved Standard, M7-A4, NCCLS 17(2),
20 (1997)). Using the method of "Approved Standard M7-A4", it is possible to determine inhibition concentrations and thus to ascertain the resistance of the investigated strain of bacteria.

The plasmid to be investigated, in the present case pTET3,
25 is then isolated from strain LP-6 as described above and used to transform a suitable control or indicator strain, in the present case strain ATCC13032. Methods for transforming coryneform bacteria are described, for example, in Thierbach et al. (Applied and Environmental
30 Microbiology 29, 356-362 (1988)), in Liebl et al. (FEMS Microbiology Letters 65, 299-304 (1989)) or in Dunican et al. (Bio/Technology 7, 1067-1070 (1989)). Selection is performed on conventional, complex nutrient media, such as

for example brain-heart bouillon or Luria-Bertani medium, which are supplemented with the appropriate antibiotics. The antibiotic and the concentration thereof for this selection process is determined on the basis of the above-mentioned "Approved Standard, M7-A4". In this manner, strain ATCC13032[pTET3], is obtained by selection for tetracycline resistance. The resistance/sensitivity of strain ATCC13032[pTET3] and of the control strain ATCC13032 is then investigated using the above-mentioned method, yielding the result that strain ATCC13032[pTET3] is resistant to the antibiotics tetracycline, streptomycin, spectinomycin and sulfamethoxazole.

This antibiotic resistance was further characterised by cloning and sequencing. To this end, plasmid pTET3 is isolated from strain LP-3 or ATCC13032[pTET3], treated with suitable restriction enzymes, mixed with cloning vectors treated in the same manner and treated with T4 DNA ligase. The ligation mixture is transferred by transformation into a suitable cloning host of *Escherichia coli*. Selection for transformants is performed on a complex nutrient medium, which is supplemented with the appropriate antibiotic. The person skilled in the art will find instructions relating to this method in Sambrook et al. Examples of suitable cloning vectors are pUC19 (Yanish-Perron et al., Gene 33, 103-119 (1985)), pK18mob2 (Tauch et al., Plasmid 40, 126-139 (1998)) or pCR2.1 (Invitrogen BV, Groningen, Netherlands). Suitable hosts are in particular those *E. coli* strains with restriction and recombination defects. One example of such a strain is the strain DH5αMCR, which has been described by Grant et al. (Proceedings of the National Academy of Sciences USA, 87, 4645-4649 (1990)). Transformation methods are described, for example, in Hanahan (Journal of Molecular Biology 166, 577-580 (1983)) or Tauch et al. (Plasmid 40, 126-139 (1998)). Transformant

selection is performed by using the antibiotics to which plasmid pTET3 imparts resistance. The plasmid DNA of the resultant transformants is then isolated and the cloned DNA fragments of plasmid pTET3 are sequenced. The sequences are then analysed as described above and compared with databases of collected DNA sequences.

The inventors discovered in this manner that the genes which impart resistance to the antibiotics tetracycline, streptomycin, spectinomycin and sulfamethoxazole are located on a continuous DNA fragment. This DNA fragment is shown as a restriction map in Figure 5. The DNA portion containing the genes tetR, tetA and aadA is shown as a sequence in SEQ ID NO:6 and is provided by the invention.

The amino acid sequences of the protein encoded by the particular gene were furthermore deduced from the ascertained DNA sequence. SEQ ID NO:7 shows the deduced amino acid sequence of the tetracycline resistance protein TetA encoded by the tetA gene and SEQ ID NO:8 shows the deduced amino acid sequence of the spectinomycin/streptomycin resistance protein AadA encoded by the aadA gene. SEQ ID NO:9 shows the coding region of the tetR gene and SEQ ID NO:10 the amino acid sequence of the tetracycline resistance repressor protein TetR.

Coding DNA sequences arising from SEQ ID NO:6 based on the degeneracy of the genetic code are also provided by the present invention. DNA sequences which hybridise with SEQ ID NO:1 or parts of SEQ ID NO:1 are similarly provided by the invention. Conservative substitutions of amino acids in proteins, for example the substitution of glycine for alanine or of aspartic acid for glutamic acid, are known to those of skill in the art as "sense mutations", which result in no fundamental change in activity of the protein, i.e. they are functionally neutral. Amino acid sequences

arising in a corresponding manner from SEQ ID NOS:7, 8 and 10 are also provided by the present invention.

The DNA fragments of plasmids pTET3 and pCRY4 from *Corynebacterium glutamicum* strain LP-6 may then be combined with DNA fragments of known plasmids of other microorganisms, such as for example *Escherichia coli* or *Corynebacterium glutamicum*, to yield further, novel plasmid vectors. For the purposes of the present invention, it is preferred to use plasmid DNA from other strains of the species *Corynebacterium glutamicum*. This approach, known as self cloning, has the advantage that no foreign nucleotide sequences are introduced in the species *Corynebacterium glutamicum*. Such further developed plasmid vectors may consist solely of constituents of the novel plasmid pTET3, i.e. of a replication region and at least one antibiotic resistance region, which is used as a selection marker. One example of such a vector is the plasmid vector pSELF3-1 shown in Figure 6. These vectors may, however, also be composed of constituents of a known plasmid and constituents of pTET3 or pCRY4. One example of such a vector is the plasmid vector pSELF1-1 shown in Figure 7, in which the known cryptic plasmid pGA1 (U.S. Pat. No. 5,175,108) has been provided with the tetA gene which imparts tetracycline resistance of pTET3.

The plasmid vectors constructed from the novel plasmids pTET3 and pCRY4 may advantageously be used for the fermentative production of industrially interesting metabolites such as amino acids, vitamins and nucleotides.

For example, within the framework of the present invention, a lysC(FBR) allele of *C. glutamicum* which encodes a feed-back resistant aspartate kinase was cloned into *C. glutamicum* ATCC13032 by means of pSELF1-1. In this manner,

a self-cloned lysine producing strain of *C. glutamicum* was produced.

By way of further example, the panD gene coding for aspartate α -decarboxylase from *C. glutamicum* was cloned
5 into the *C. glutamicum* strain ATCC13032 Δ ilvA by means of pSELF1-1. In this manner, a self-cloned pantothenic acid producing strain of *C. glutamicum* was produced.

One very particular advantage of the novel plasmids pTET3 and pCRY4 and further plasmid vectors based thereon is that
10 they exhibit an unusually high level of compatibility with known plasmids or plasmid vectors.

It was thus found that plasmid pTET3 may coexist in the presence of or is compatible with plasmid vectors based on pGA1 (U.S. Pat. No. 5,175,108), pAG3 (U.S. Pat. No.
15 5,158,891), pBL1 (Santamaria et al., Journal of General Microbiology 130, 2237-2246 (1984)) or on pHM1519 (Miwa et al., Agricultural and Biological Chemistry 48, 2901-2903 (1984)). This compatibility of pTET3 is still retained when the host cell concerned already contains two or more known
20 plasmid vectors, for example a pBL1 derivative and simultaneously a pHM1519 derivative. pTET3's capacity to coexist with known plasmids or plasmid vectors is ensured over a sufficiently long period of time or for a sufficiently large number of generations.

25 It has furthermore been found that plasmid pCRY4 may coexist in the simultaneous presence of or is compatible with plasmids pTET3, pGA1 (U.S. Pat. No. 5,175,108) and pGA2 (U.S. Pat. No. 5,175,108) in the presence of plasmid vectors based on pAG3 (U.S. Pat. No. 5,158,891), pBL1
30 (Santamaria et al., Journal of General Microbiology 130, 2237-2246 (1984)) or on pHM1519 (Miwa et al., Agricultural and Biological Chemistry 48, 2901-2903 (1984)). This

compatibility of pCRY3 is still retained when the host cell concerned already contains two or more known plasmid vectors, for example a pBL1 derivative and simultaneously a pHM1519 derivative. pCRY4's capacity to coexist with known plasmids or plasmid vectors is ensured over a sufficiently long period of time or for a sufficiently large number of generations.

The improved compatibility of plasmids pTET3 and pCRY4 may advantageously be used for improving strains which produce amino acids, vitamins and nucleotides. Sahm and Eggeling (Applied and Environmental Microbiology 65, 1973-1979 (1999)) thus describe the pantothenic acid producing strain ATCC13032ΔilvA [pECM3ilvBNCD, pEKEx2panBC]. This strain bears the pHM1519 derivative pECM3ilvBNCD and the pBL1 derivative pEKEx2panBC. It proved possible to achieve a distinct improvement in the performance characteristics of the stated strain, which already contains two plasmids, after transferring the panD gene by means of the plasmid vector pSELF3-1.

BRIEF DESCRIPTION OF THE DRAWINGS

- Figure 1: Restriction map of plasmid pTET3.
 - Figure 2: Restriction map of plasmid pCRY4.
 - Figure 3: Map of replication region of plasmid pTET3.
 - 5 • Figure 4: Map of replication region of plasmid pCRY4
 - Figure 5: Map of antibiotic resistance region of plasmid pTET3.
 - Figure 6: Map of plasmid vector pSELF3-1.
 - Figure 7: Map of plasmid vector pSELF1-1.
- 10 The lengths stated should be considered to be approximate.
The abbreviations and terms used have the following meaning:

bps: Base pairs

AvrII: Restriction site for restriction enzyme AvrII

15 ClaI: Restriction site for restriction enzyme ClaI

EcoRI: Restriction site for restriction enzyme EcoRI

EcoRV: Restriction site for restriction enzyme EcoRV

FspI: Restriction site for restriction enzyme FspI

HindIII: Restriction site for restriction enzyme HindIII

20 HpaI: Restriction site for restriction enzyme HpaI

MunI: Restriction site for restriction enzyme MunI

NruI: Restriction site for restriction enzyme NruI

PstI: Restriction site for restriction enzyme PstI

SacI: Restriction site for restriction enzyme SacI
SacII: Restriction site for restriction enzyme SacII
SalI: Restriction site for restriction enzyme SalI
ScaI: Restriction site for restriction enzyme ScaI
5 SmaI: Restriction site for restriction enzyme SmaI
SpeI: Restriction site for restriction enzyme SpeI
SphI: Restriction site for restriction enzyme SphI
XbaI: Restriction site for restriction enzyme XbaI
XhoI: Restriction site for restriction enzyme XhoI
10 aadA: Gene for spectinomycin/streptomycin resistance
protein
parA: Gene for stabilisation protein ParA
sulI: Gene for the sulfamethoxazole resistance protein
repA: Gene for the replication protein RepA
15 tetA: Gene for the tetracycline resistance protein
tetR: Gene for the tetracycline repressor protein

DETAILED DESCRIPTION OF THE INVENTION

The present invention is illustrated in greater detail by
20 the following practical examples.

The following strains of bacteria were used:

Corynebacterium glutamicum LP-6 was deposited in the
context of EP-B 0 472 869 with Deutsche Sammlung für
Mikroorganismen und Zellkulturen (DSMZ, Braunschweig,
25 Germany) under number DSM5816. The storage period for

DSM5816 has been extended pursuant to rule 9.1 of the Budapest Treaty. DSM5816 has the following taxonomic features:

- Cell shape: Y-shaped branching
- 5 - Peptidoglycan: meso-diaminopimelic acid
- Mycolic acids: *Corynebacterium* mycolic acids with a high level of similarity to DSM20300
- Fatty acid pattern: fatty acid pattern typical of *Corynebacterium* with unbranched, saturated and
- 10 - unsaturated fatty acids with a high level of similarity to DSM20300.
- G+C content: 55.1%
- 16S rDNA sequence: 98.6% identical in comparison with DSM20300
- 15 - DNA-DNA homology: 81.6% to DSM20300

Corynebacterium glutamicum ATCC13032 was obtained from the American Type Culture Collection (Manassas, USA).

- Corynebacterium glutamicum* ATCC13032ΔilvA is deposited with Deutsche Sammlung für Mikroorganismen und Zellkulturen
- 20 (DSMZ, Braunschweig, Germany) under number DSM12455.

- The general genetic methods stated and the nutrient media used in the following Examples are described in Sambrook et al. (Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989)). Electrically-assisted
- 25 transfer of plasmid DNA was performed using the method of Liebl et al. (FEMS Microbiology Letters 65, 299-304 (1989)).

- The DNA fragments described in the following Examples were sequenced in accordance with the dideoxy chain termination
- 30 method according to Sanger et al. (Proceedings of the National Academy of Sciences USA 74, 5463-5467 (1977)). The resultant raw sequence data were processed using the

"STADEN software package" (Staden, Molecular Biotechnology 5, 233-241 (1996)). Computer-aided coding range analysis was performed using XNIP software (Staden, Molecular Biotechnology 5, 233-241 (1996)). Further sequence analysis was performed using the "BLAST programs" (Altschul et al., Nucleic Acids Research 25, 3389-3402 (1997)).

Example 1

Isolation and characterisation of the novel plasmids pTET3 and pCRY4

10 In order to identify novel plasmids and isolate plasmid DNA, the bacterial strain *Corynebacterium glutamicum* LP-6 was cultured in LB medium and isolated in accordance with the instructions given in "NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)"

15 (Clontech Laboratories GmbH, Heidelberg, Germany, 1997). The isolated plasmid DNA was separated in a 0.8% agarose gel and the plasmid bands corresponding to the novel plasmids pTET3 and pCRY4 were each reisolated separately from the agarose gel. The experimental procedure was in

20 accordance with "QIAEX II Handbook for DNA Extraction from Agarose Gels" (Qiagen GmbH, Hilden, Germany, 1997). The reisolated plasmid DNA of pTET3 was then digested in accordance with the manufacturers' instructions with the restriction enzymes AvrII, MuiI (New England Biolabs GmbH,

25 Schwalbach, Germany), HpaI, ScaI, XbaI (Pharmacia Biotech Europe GmbH, Freiburg, Germany) and SpeI (Roche Diagnostics GmbH, Mannheim, Germany) in each case individually and in combination. The restriction batches were then separated in a 0.8% agarose gel. By comparing the resultant DNA

30 fragments with DNA fragments of known length (DNA Molecular Weight Marker X, Roche Diagnostics GmbH, Mannheim, Germany), the restriction map of plasmid pTET3 from

Corynebacterium glutamicum LP-6 shown in Figure 1 was determined.

The reisolated plasmid DNA of the novel plasmid pCRY4 from *Corynebacterium glutamicum* LP-6 was then digested in accordance with the manufacturers' instructions with the restriction enzymes AvrII (New England Biolabs GmbH, Schwalbach, Germany), EcoRV, HpaI and ClaI (Pharmacia Biotech Europe GmbH, Freiburg, Germany) in each case individually and in combination. The restriction batches were then separated in a 0.8% agarose gel. By comparing the resultant DNA fragments with DNA fragments of known length (DNA Molecular Weight Marker X, Roche Diagnostics GmbH, Mannheim, Germany), the restriction map of plasmid pCRY4 from *Corynebacterium glutamicum* LP-6 shown in Figure 2 was determined.

Example 2

Isolation and sequencing of the replication region of plasmid pTET3

In order to isolate a DNA region which is required for
5 stable replication of the novel plasmids in coryneform
bacteria, plasmid DNA was initially isolated from
Corynebacterium glutamicum LP-6 by alkaline treatment of
the bacterial cells. The experimental method is described
in detail in the instructions for "NucleoBond Nucleic Acid
10 Purification Kits and Cartridges User Manual (PT3167-1)"
(Clontech Laboratories GmbH, Heidelberg, Germany, 1997).
The resultant DNA preparation of *Corynebacterium glutamicum*
LP-6 was then separated in a 0.8% agarose gel and
investigated for the presence of plasmid bands. The
15 identified plasmid bands from *Corynebacterium glutamicum*
LP-6 were assigned to the known plasmids pGA1 and pGA2
(U.S. Pat. No. 5,175,108) and the novel plasmids pTET3 and
pCRY4. The plasmid bands corresponding to the plasmid pTET3
were reisolated from the agarose gel (c.f. Example 1). The
20 experimental procedure may be found in "QIAEX II Handbook
for DNA Extraction from Agarose Gels" (Qiagen GmbH, Hilden,
Germany, 1997). The reisolated plasmid DNA was then
digested with the restriction enzymes AvrII (New England
Biolabs GmbH, Schwalbach, Germany) and HpaI (Pharmacia
25 Biotech Europe GmbH, Freiburg, Germany) and cloned into the
vector pK18mob2 (Tauch et al., Plasmid 40, 126-139 (1998))
which had been cut with the restriction enzymes XbaI and
SmaI (Pharmacia Biotech Europe GmbH, Freiburg, Germany).
DNA restriction and DNA ligation using the enzyme T4 DNA
30 ligase (Roche Diagnostics GmbH, Mannheim, Germany) were
performed in accordance with the manufacturer's
instructions. This ligation mixture was then electroporated
into strain *Corynebacterium glutamicum* ATCC13032. Selection

was performed on LB agar containing 25 µg/ml of kanamycin. After 48 hours' incubation at 30°C, colonies were isolated which contained plasmids. The presence of plasmids in the transformed bacterial cells was shown using an alkaline

5 lysis method in accordance with the instructions in "QIAGEN Plasmid Mini Handbook for Plasmid Mini Kit" (Qiagen GmbH, Hilden, Germany, 1997). The isolated plasmid was named pTET3-Rep. Restriction analysis of pTET3-Rep and a comparison of the fragment lengths obtained with DNA

10 fragments of known length (DNA Molecular Weight Marker X, Roche Diagnostics GmbH, Mannheim, Germany) revealed that pTET3-Rep consists of the cloning vector pK18mob2, which contains a DNA fragment from pTET3 of an approximate size of 4500 base pairs (bp).

15 For the purposes of double-stranded DNA sequencing of the approximately 4500 bp DNA fragment from pTET3-Rep, the DNA was isolated in accordance with the instructions of "NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)" (Clontech Laboratories GmbH,

20 Heidelberg, Germany, 1997). Sequencing and subsequent coding region analysis revealed two open reading frames (ORFs) on the sequenced DNA fragment. Figure 3 shows a restriction map of the sequenced DNA fragment of pTET3-Rep, which also indicates the position of the two identified

25 ORFs. Analysis with the BLAST programs revealed that ORF1 encodes a stabilisation protein designated as ParA and that ORF2 encodes a replication protein designated as RepA. ORF1 was accordingly designated as the parA gene and ORF2 as the repA gene. The DNA sequence of the cloned fragment is set

30 forth in SEQ ID NO:1. The amino acid sequence of the stabilisation protein ParA, deduced from the DNA sequence, is set forth in SEQ ID no. 2 and the deduced amino acid sequence of the replication protein RepA is set forth in SEQ ID NO:3.

Example 3

Determination of the copy number of the pTET3 replicon in *Corynebacterium glutamicum* ATCC13032

In order to determine the copy number of plasmid pTET3-Rep,
5 the bacterial strain *Corynebacterium glutamicum* ATCC13032
[pTET3-Rep] was cultured for 20 hours at 30°C in 100 ml of
LB medium with 25 µg/ml of kanamycin. The total DNA of the
strain was then isolated from 25 ml of bacterial culture
using the method according to Tauch et al. (Plasmid 34,
10 119-131 (1995)). The resultant DNA was treated for 20
minutes at 37°C with 20 µg/ml of RNase/DNase-free (Roche
Diagnostics GmbH, Mannheim, Germany) and, after phenol
extraction, separated electrophoretically in 0.8% agarose
gel. The agarose gel stained with ethidium bromide was
15 photographed under UV light with a Cybertech CS1 camera
system (Cybertech GmbH, Berlin, Germany) and the negative
image was digitised with an HP Scanjet 6100 C/T Optical
Scanner (Hewlett-Packard Co., Palo Alto, CA, USA). The band
density of the DNA was quantified densitometrically using
20 the Wincam computer system from Cybertech GmbH (Berlin,
Germany). The copy number was calculated in accordance with
the method of Miwa et al. (Agricultural and Biological
Chemistry 48, 2901-2903 (1984)) assuming a chromosome size
of 3082 kb (Bathe et al., Molecular and General Genetics
25 252, 255-265 (1996)) and revealed a value of 15 plasmids
per chromosome for plasmid pTET3-Rep in *Corynebacterium*
glutamicum ATCC13032.

Example 4

Isolation and sequencing of the replication region of
30 plasmid pCRY4

In order to isolate the DNA region which is required for stable replication of the novel plasmid pCRY4 in coryneform bacteria, plasmid DNA was initially isolated from *Corynebacterium glutamicum* LP-6 by alkaline treatment of the bacterial cells. The experimental method may be found in the instructions for "NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)" (Clontech Laboratories GmbH, Heidelberg, Germany, 1997). The resultant DNA preparation of *Corynebacterium glutamicum* LP-6 was then separated in a 0.8% agarose gel and investigated for the presence of a pCRY4 plasmid band. The identified plasmid band corresponding to the novel plasmid pCRY4 was then reisolated from the agarose gel (c.f. Example 1). The experimental procedure may be found in "QIAEX II Handbook for DNA Extraction from Agarose Gels" (Qiagen GmbH, Hilden, Germany, 1997). The reisolated plasmid DNA was then digested with the restriction enzyme SphI (Pharmacia Biotech Europe GmbH, Freiburg, Germany) and cloned into the vector pK18mob2 (Tauch et al., Plasmid 40, 126-139 (1998)) which had been cut with the restriction enzyme SphI. DNA restriction and DNA ligation using the enzyme T4 DNA ligase (Roche Diagnostics GmbH, Mannheim, Germany) were performed in accordance with the manufacturer's instructions. The ligation mixture was then transferred with electrical assistance into the coryneform bacterial strain *Corynebacterium glutamicum* ATCC13032. Selection was performed on LB agar containing 25 µg/ml of kanamycin. After 48 hours' incubation at 30°C, colonies containing plasmids were isolated. The presence of plasmids in the transformed bacterial cells was demonstrated by an alkaline lysis method in accordance with the instructions in "QIAGEN Plasmid Mini Handbook for Plasmid Mini Kit" (Qiagen GmbH, Hilden, Germany, 1997). The isolated plasmid was named pCRY4-Rep. Restriction analysis of pCRY4-Rep and a comparison of the fragment lengths obtained with DNA

fragments of known length (DNA Molecular Weight Marker X, Roche Diagnostics GmbH, Mannheim, Germany) revealed that pCRY4-Rep contains an approximately 1900 bp DNA fragment.

For the purposes of double-stranded DNA sequencing of the approximately 1900 bp DNA fragment from pCRY4-Rep, the DNA was isolated in accordance with the instructions of "NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)" (Clontech Laboratories GmbH, Heidelberg, Germany, 1997). DNA sequencing and computer-aided coding region analysis allowed an open reading frame (ORF1) to be identified on the sequenced DNA fragment. Figure 4 shows the restriction map of the sequenced DNA fragment of pCRY4-Rep, which also indicates the position of the identified ORF. Analysis with the BLAST programs revealed that ORF1 encodes a replication protein (RepA), which was designated as the repA gene. The DNA sequence of the cloned fragment is reproduced as SEQ ID NO:4, while the deduced amino acid sequence of the replication protein RepA is shown in SEQ ID NO:5.

Example 5

Determination of the copy number of the pCRY4 replicon in *Corynebacterium glutamicum* ATCC13032

In order to determine the copy number of plasmid pCRY4-Rep, the bacterial strain *Corynebacterium glutamicum* ATCC13032 [pCRY4-Rep] was cultured for 20 hours at 30°C in 100 ml of LB medium with 25 µg/ml of kanamycin. The total DNA of the strain was then isolated from 25 ml of bacterial culture using the method according to Tauch et al. (Plasmid 34, 119-131 (1995)). The resultant DNA was treated for 20 minutes at 37°C with 20 µg/ml of RNase/DNase-free (Roche Diagnostics GmbH, Mannheim, Germany) and, after phenol extraction, separated electrophoretically in 0.8% agarose

gel. The agarose gel stained with ethidium bromide was photographed under UV light with a Cybertech CS1 camera system (Cybertech GmbH, Berlin, Germany) and the negative image was digitised with an HP Scanjet 6100 C/T Optical Scanner (Hewlett-Packard Co., Palo Alto, CA, USA). The band density of the DNA was quantified densitometrically using the Wincam computer system from Cybertech GmbH (Berlin, Germany). The copy number was calculated in accordance with the method of Miwa et al. (Agricultural and Biological Chemistry 48, 2901-2903 (1984)) assuming a chromosome size of 3082 kb (Bathe et al., Molecular and General Genetics 252, 255-265 (1996)) and revealed a value of 3 plasmids per chromosome for plasmid pCRY4-Rep in *Corynebacterium glutamicum* ATCC13032.

15 Example 6

Isolation and sequencing of the antibiotic resistance region of plasmid pTET3

In order to identify antibiotic resistance regions on the novel plasmids pTET3 or pCRY4, the resistant test strain *Corynebacterium glutamicum* LP-6 and the sensitive control strain *Corynebacterium glutamicum* ATCC13032 were initially cultured in the presence and absence of various antibiotics and antibiotic concentrations in accordance with the experimental method of the National Committee of Clinical Laboratory Standards (National Committee of Clinical Laboratory Standards, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard, M7-A4 (1997)). The antibiotics required for this test, *inter alia* the antibiotics tetracycline, spectinomycin, streptomycin and sulfamethoxazole, were obtained from Sigma-Aldrich Chemie GmbH (Deisenhofen, Germany) and used in the concentrations stated in "Approved Standard M7-A4". The nutrient medium required for this

test, "MÜLLER-HINTON bouillon" was obtained from Merck KGaA (Darmstadt, Germany) and used in accordance with the manufacturer's instructions. Using the method of "Approved Standard M7-A4", it is possible to determine inhibition concentrations (Table 1) and to identify the resistance of the bacterial strain *Corynebacterium glutamicum* LP-6 to the antibiotics tetracycline, spectinomycin, streptomycin and sulfamethoxazole. Plasmid DNA isolated from *Corynebacterium glutamicum* LP-6 using an alkaline lysis method ("NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)", Clontech Laboratories GmbH, Heidelberg, Germany, 1997) was then transferred with electrical assistance into *Corynebacterium glutamicum* ATCC13032. Selection was performed directly for the presence of the identified tetracycline resistance in the primary selection on LB agar containing 5 µg/ml of tetracycline. The presence of a plasmid in the transformed bacterial strain *Corynebacterium glutamicum* ATCC13032 was then demonstrated by an alkaline lysis method ("NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)", Clontech Laboratories GmbH, Heidelberg, Germany, 1997). Restriction analysis of the isolated plasmid DNA and comparison of the resultant fragment lengths with DNA fragments of known length (DNA Molecular Weight Marker X, Roche Diagnostics GmbH, Mannheim, Germany) and with DNA fragments of plasmid pTET3 revealed that the transformed plasmid which imparts tetracycline resistance is the plasmid pTET3. The transformed strain was named *Corynebacterium glutamicum* ATCC13032 [pTET3].

Another resistance test with the isolated, resistant test strain *Corynebacterium glutamicum* ATCC13032 [pTET3] and the sensitive control strain *Corynebacterium glutamicum* ATCC13032 in accordance with the instructions of the National Committee of Clinical Laboratory Standards in the

presence of various concentrations of the antibiotics tetracycline, spectinomycin, streptomycin and sulfamethoxazole demonstrated that the test strain *Corynebacterium glutamicum* ATCC13032 [pTET3] is resistant to these antibiotics (Table 1).

Table 1

Minimum inhibition concentration (μg of antibiotic per ml) of various *Corynebacterium glutamicum* strains

Antibiotic	ATCC13032	LP-6	ATCC13032 [pTET3]
Tetracycline	≤ 0.75	≤ 12	≤ 12
Spectinomycin	≤ 50	> 2000	> 2000
Streptomycin	≤ 0.5	≤ 100	≤ 100
Sulfamethoxazole	≤ 150	≤ 300	≤ 300

The symbols are defined as follows:

- > : The minimum inhibition concentration is greater than the stated value.
- 15 \leq : The minimum inhibition concentration is less than or equal to the stated value.

The antibiotic resistance of pTET3 was further characterised by reisolating the plasmid DNA from *Corynebacterium glutamicum* ATCC13032 [pTET3] using an alkaline lysis method ("NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)",

Clonetech Laboratories GmbH, Heidelberg, Germany, 1997). The plasmid DNA was then cleaved with the restriction enzymes HindIII or SacI (Pharmacia Biotech Europe GmbH, Freiburg, Germany) and ligated into the *Escherichia coli* cloning vectors pK18mob2 (Tauch et al., Plasmid 40, 126-139 (1998)) or pUV19 (Pharmacia Biotech Europe GmbH, Freiburg, Germany). DNA restriction and DNA ligation using the enzyme T4 DNA ligase (Roche Diagnostics GmbH, Mannheim, Germany) were performed in accordance with the manufacturer's instructions. The ligation batch was then electroporated into the bacterial strain *Escherichia coli* DH5 α MCR (Tauch et al., FEMS Microbiology Letters 123, 343-348 (1994)). After selection on LB agar containing 5 μ g/ml of tetracycline or 250 μ g/ml of spectinomycin, transformed colonies were obtained, the plasmid vectors of which contained sections of DNA from plasmid pTET3. The presence of plasmids vectors was proven by an alkaline lysis method ("QIAGEN Plasmid Miniprep Handbook for Plasmid DNA", Qiagen GmbH, Hilden, Germany, 1997). Restriction analysis of the isolated plasmid DNA and comparison of the resultant fragment lengths with DNA fragments of known length revealed that the isolated plasmid named pTET3-H9 consists of the plasmid vector pK18mob2 and an approximately 4000 bp DNA fragment from pTET3, and that the isolated plasmid named pXCS10 consists of the plasmid vector pUC19 (Pharmacia Biotech Europe GmbH, Freiburg, Germany) and an approximately 6750 bp DNA fragment from pTET3. The plasmid vector pTET3-H9 obtained from cloning with the restriction enzyme HindIII, imparts tetracycline resistance (5 μ g/ml) in *Escherichia coli* DH5 α MCR, while the plasmid vector pXCS10 obtained from cloning with the restriction enzyme SacI imparts resistance to the antibiotics spectinomycin (250 μ g/ml), streptomycin (250 μ g/ml) and sulfamethoxazole (300 μ g/ml). A comparison of the restriction analyses of

the cloned DNA fragments of pTET3 in plasmid vectors pTET3-H9 and pXCS10 moreover demonstrated that both DNA fragments overlap by approximately 2400 bp and may thus be combined into a continuous DNA strand of a length of approximately 8350 bp.

For the purposes of double-stranded DNA sequencing of a continuous, approximately 7300 bp DNA fragment from pTET3 which imparts resistance to tetracycline, spectinomycin and streptomycin, DNA was isolated from plasmids pTET3-H9 and pXCS10 in accordance with the instructions of "QIAprep Miniprep Handbook for Purification of Plasmid DNA" (Qiagen GmbH, Hilden, Germany, 1997). After sequencing and sequence analysis, four open reading frames (ORFs) could be determined on the sequenced DNA fragment. Figure 5 shows a restriction map of the sequenced DNA region of pTET3 and the position of the identified open reading frames (ORFs). Analysis revealed that ORF1 represents a tetR gene which encodes a tetracycline resistance repressor protein (TetR), ORF2 represents a tetA gene which encodes a tetracycline resistance protein (TetA), ORF3 represents an aadA gene which encodes a spectinomycin/streptomycin resistance protein (AadA) and ORF4 represents a sulI gene which encodes a sulfamethoxazole resistance protein (SulI). The DNA sequence of the resistance region of pTET3 is reproduced in SEQ ID NO:6. The amino acid sequence of the tetracycline resistance protein (TetA), deduced from the sequence data, is shown in SEQ ID NO:7 and the amino acid sequence of the spectinomycin/streptomycin resistance protein (AadA), deduced from the sequence data, is shown in SEQ ID NO:8. The coding region of the tetR gene which encodes the tetracycline resistance repressor protein (TetR) is also shown in SEQ ID NO:9 and the deduced amino acid sequence in SEQ ID NO:10.

Example 7

Coexistence of plasmid pTET3 with known coryneform plasmids in *Corynebacterium glutamicum* ATCC13032

The bacterial strain *Corynebacterium glutamicum* ATCC13032
5 [pTET3] produced in Example 6 was used to analyse the coexistence of the novel plasmid pTET3 from *Corynebacterium glutamicum* LP-6 with known coryneform plasmids.

Electrocompetent cells of this strain were produced, into which plasmid vectors consisting of known plasmids of
10 coryneform bacteria and selection marker fractions were transferred. Plasmid vectors pGA1-KE12, pAG3-Xba, pEBM2 (Tauch et al., Archives of Microbiology 169, 303-312 (1998)), pECM2 (Tauch et al., FEMS Microbiology Letters 123, 343-348 (1994)) and pECM3 were selected for this DNA
15 transfer. Plasmid pGA1-KE12 is an EcoRI fusion of the cryptic plasmid pGA1 from *Corynebacterium glutamicum* LP-6 with vector pK18mob2 (Tauch et al., Plasmid 40, 126-139 (1998)). Plasmid pAG3-Xba is an XbaI fusion of pAG3 and pK18mob2. Plasmid pECM3 is a BamHI-BgIII deletion of pECM2.
20 Once transfer of the plasmid vectors pGA1-KE12 (pGA1 derivative), pAG3-Xba (pAG3 derivative), pEBM2 (pBL1 derivative) and pECM2 (pHM1519 derivative), which impart kanamycin resistance, was complete, selection was performed on LB agar containing 25 µg/ml of kanamycin. Plasmid pECM3,
25 a pHM1519 derivative, which imparts chloramphenicol resistance, was additionally transferred into the resultant bacterial strain *Corynebacterium glutamicum* ATCC13032 [pTET3, pEBM2], which bears the plasmids pTET3 and pEBM2. After DNA transfer, selection was performed on LB agar
30 containing 7.5 µg/ml of chloramphenicol (Sigma-Aldrich Chemie GmbH, Deisenhofen, Germany). In order to confirm completion of the plasmid transfer, plasmid DNA was isolated from the resultant strains or transformants

("NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)", Clontech Laboratories GmbH, Heidelberg, Germany, 1997) and detected in 0.8% agarose gel.

5 In this manner, the following strains of *Corynebacterium glutamicum* were produced:

- ATCC13032 [pTET3, pGA1-KE12]
- ATCC13032 [pTET3, pAG3-Xba]
- ATCC13032 [pTET3, pEBM2]
- 10 • ATCC13032 [pTET3, pECM2]
- ATCC13032 [pTET3, pEBM2, pECM3].

In order to provide further evidence of the coexistence of the novel plasmid pTET3 with known plasmid vectors, the strains produced were initially cultured for 24 hours at 30°C in LB medium, which had been supplemented with the appropriate antibiotics (5 µg/ml of tetracycline, 25 µg/ml of kanamycin and 10 µg/ml of chloramphenicol). 1 ml portions of each of the cultures were then washed twice in antibiotic-free LB medium. Dilution series of the washed bacterial suspensions were prepared in LB medium and suspensions of 0.1 ml, which contained 10⁴ cells, were transferred in each case onto 100 ml of antibiotic-free and antibiotic-containing LB medium. These cultures were again cultured at 30°C over approximately 25 generations and growth monitored by measuring optical density at a wavelength of 580 nm using a spectrophotometer (Pharmacia LKB Novaspec II, Pharmacia, Freiburg, Germany). The cultures were cultured at least up to an optical density of 8 (optical density of 1 corresponds to 4×10⁸ cells per ml).

The plasmid DNA was then isolated from the cultures and separated in 0.8% agarose gel. The resultant plasmid bands were identical under both culture conditions, i.e. in the presence and absence of antibiotics, and each exhibited the presence of plasmid pTET3 and of the transformed plasmid vector, i.e. pGA1-KE12, pAG3-Xba, pEBM2, pECM2, and pEBM2 plus pECM3.

Example 8

- Coexistence of plasmid pCRY4 with other coryneform plasmids in *Corynebacterium glutamicum* LP-6

Corynebacterium glutamicum LP-6, in which pCRY4 already coexists with plasmids pGA1, pGA2 and pTET3, was used to analyse the coexistence of plasmid pCRY4 with known coryneform plasmids.

- Further plasmid vectors consisting of known coryneform plasmids and selection marker fractions were transferred into this bacterial strain. Plasmid vectors pAG3-Xba, pEBM2 (Tauch et al., Archives of Microbiology 169, 303-312 (1998)), pECM2 (Tauch et al., FEMS Microbiology Letters 123, 343-348 (1994)) and pECM3 were used for this DNA transfer. Plasmid pECM3 is a BamHI-BgIII deletion of pECM2. Transfer of the plasmid vectors pAG3-Xba (pAG3 derivative), pEBM2 (pBL1 derivatives) and pECM2 (pHM1519 derivative) was selected on LB agar containing 25 µg/ml of kanamycin. The plasmid pECM3, a pHM1519 derivative, which imparts chloramphenicol resistance was additionally transferred into the resultant bacterial strain *Corynebacterium glutamicum* LP-6 [pEBM2], which bears the plasmids pGA1, pGA2, pTET3, pCRY4 and pEBM2. After DNA transfer, selection was performed on LB agar containing 7.5 µg/ml of chloramphenicol. In order to confirm successful plasmid transfer, plasmid DNA was isolated from the resultant

strains or transformants ("NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)", Clontech Laboratories GmbH, Heidelberg, Germany, 1997) and detected in 0.8% agarose gel.

5 In this manner, the following strains of *Corynebacterium glutamicum* were produced:

- LP-6 [pAG3-Xba]
 - LP-6 [pEBM2]
 - LP-6 [pECM2]
- 10 • LP-6 [pEBM2, pECM3].

(It should be noted that the recipient strain, *Corynebacterium glutamicum* LP-6, already contains plasmids pGA1, pGA2, pTET3 and pCRY4.)

In order to provide further evidence of the coexistence of
15 the plasmid pCRY4 with known plasmid vectors, the strains produced were initially cultured for 24 hours at 30°C in LB medium, which had been supplemented with the appropriate antibiotics (5 µg/ml of tetracycline, 25 µg/ml of kanamycin and 10 µg/ml of chloramphenicol). 1 ml portions of the
20 bacterial cultures were then washed twice in antibiotic-free LB medium. Dilution series of the washed bacterial suspensions were prepared in LB medium and suspensions of 0.1 ml, which contained 10⁴ cells, were transferred in each case onto 100 ml of antibiotic-free and antibiotic-
25 containing LB medium. These cultures were again cultured at 30°C over approximately 25 generations and growth monitored by measuring optical density at a wavelength of 580 nm using a spectrophotometer (Pharmacia LKB Novaspec II, Pharmacia, Freiburg, Germany). The cultures were cultured
30 at least up to an optical density of 8 (optical density of

- 1 corresponds to 4×10^8 cells per ml). The plasmid DNA was then isolated from the cultures and separated in 0.8% agarose gel. The resultant plasmid bands were identical under selective and non-selective culture conditions, i.e. in the presence and absence of antibiotics, and each exhibited the presence of plasmids pGA1, pGA2, pTET3 and pCRY4 and of the transformed plasmid vector, i.e. pAG3-Xba, pEBM2, pECM2 and pEBM2 plus pECM3.

Example 9

- 10 Construction of plasmid vector pSELF3-1 from pTET3

- In order to construct a plasmid vector consisting solely of components of the novel plasmid pTET3, the total plasmid DNA from *Corynebacterium glutamicum* LP-6 was isolated by alkaline treatment of the bacterial cells ("NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT3167-1)", Clontech Laboratories GmbH, Heidelberg, Germany, 1997). The resultant DNA preparation was then separated in a 0.8% agarose gel. The plasmid band corresponding to the novel plasmid pTET3 was reisolated from the agarose gel ("QIAEX II Handbook for DNA Extraction from Agarose Gels", Qiagen GmbH, Hilden, Germany). The reisolated plasmid DNA was then digested with the restriction enzyme XhoI (Pharmacia Biotech Europe GmbH, Freiburg, Germany) in accordance with the manufacturer's instructions. The restriction batch was separated in a 0.8% agarose gel and an approximately 2500 bp DNA fragment, on which, according to DNA sequence data (Example 6), the tetracycline resistance region is located, was reisolated. The isolated pTET3 DNA was then cleaved with the restriction enzymes AvrII (New England Biolabs GmbH, Schwalbach, Germany) and HpaI (Pharmacia Biotech Europe GmbH, Freiburg, Germany). The cleavage batch was also separated in a 0.8% agarose gel and the approximately 4500

bp DNA fragment, on which, according to the DNA sequence information, the replication region of pTET3 is located, was reisolated. The projecting DNA ends of both the reisolated DNA fragments were then filled in with the enzyme Klenow polymerase. The fill-in reaction with the enzyme Klenow polymerase was performed in accordance with the manufacturer's instructions (Roche Diagnostics GmbH, Mannheim, Germany). The filled in DNA fragments were then ligated together by the enzyme T4 DNA ligase (Roche Diagnostics GmbH, Mannheim, Germany) in accordance with the manufacturer's instructions. The ligation mixture was transferred into *Corynebacterium glutamicum* ATCC13032 by electroporation. Selection was performed on LB agar containing 5 µg/ml of tetracycline. After 48 hours' incubation at 30°C, colonies were isolated which contain the novel plasmid vector. The presence of plasmid vector in the transformed bacterial cells was demonstrated using an alkaline lysis method ("QIAGEN Plasmid Mini Handbook for Plasmid Mini Kit", Qiagen GmbH, Hilden, Germany, 1997). The isolated plasmid was named pSELF3-1. Restriction analyses of pSELF3-1 and a comparison of the fragment lengths obtained with DNA fragments of known length yielded the restriction map in Figure 6.

Due to this construction scheme, plasmid pSELF3-1 consists solely of DNA fragments of the novel plasmid pTET3 and thus of DNA which originates solely from *Corynebacterium glutamicum*.

Example 10

Construction of plasmid vector pSELF1-1

Plasmid vector pSELF1-1 was produced from known plasmid pGA1 (US-A 5,175,108) using the tetracycline resistance gene from pTET3 (c.f. Examples 1 and 6).

To this end, the total plasmid DNA of *Corynebacterium glutamicum* LP-6 was initially isolated by alkaline treatment of the bacterial cells ("NucleoBond Nucleic Acid Purification Kits and Cartridges User Manual (PT1997-6)", Clonetech Laboratories GmbH, Heidelberg, Germany, 1997). The resultant DNA preparation was separated in a 0.8% agarose gel. The plasmid bands corresponding to the known plasmid pGA1 and the novel plasmid pTET3 were reisolated from the agarose gel ("QIAEX II Handbook for DNA Extraction from Agarose Gels", Qiagen GmbH, Hilden, Germany). The isolated DNA from pGA1 was then cleaved with the restriction enzyme SalI (Pharmacia Biotech Europe GmbH, Freiburg, Germany) in accordance with the manufacturer's instructions. The isolated plasmid DNA of pTET3 was cleaved with the restriction enzyme XhoI (Pharmacia Biotech Europe GmbH, Freiburg, Germany). The restriction batch of pTET3 was separated in a 0.8% agarose gel and an approximately 2500 bp DNA fragment, on which, according to DNA sequence data (Example 6), the tetracycline resistance region is located, was reisolated. The produced DNA fragment of pGA1 and the reisolated DNA fragment of pTET3 were then ligated together by means of T4 DNA ligase (Roche Diagnostics GmbH, Mannheim, Germany) in accordance with the manufacturer's instructions. The ligation mixture was transferred into *Corynebacterium glutamicum* ATCC13032 by electroporation. Selection was performed on LB agar containing 5 µg/ml of tetracycline. After 48 hours' incubation at 30°C, colonies were isolated which contained the novel plasmid vector. The presence of plasmid vector in the transformed bacterial cells was proven by an alkaline lysis method ("QIAGEN Plasmid Mini Handbook for Plasmid Mini Kit", Qiagen GmbH, Hilden, Germany, 1997). The isolated plasmid was named pSELF1-1. Restriction analyses of pSELF1-1 and a comparison of the fragment lengths obtained with DNA fragments of

known length yielded the restriction map which is attached as Figure 7.

Due to this construction method, plasmid pSELF1-1 consists solely of DNA fragments which originate solely from

5 *Corynebacterium glutamicum*.

Example 11

Production of lysine using pSELF1-1

In order to increase the copy number of a gene which is involved in the biosynthesis of amino acid lysine in
10 *coryneform* bacteria, the *lysC*(FBR) gene from *Corynebacterium glutamicum* was selected. The *lysC*(FBR) gene encodes a form of the enzyme aspartate kinase which is resistant to the antimetabolite S-(2-aminoethyl)cysteine and was in cloned form on the plasmid vector pJC30 (Cremer
15 et al., Applied and Environmental Microbiology 57, 1746-1752 (1991)).

In order to clone the *lysC*(FBR) gene into the plasmid vector pSELF1-1 described in Example 10, plasmid DNA of pSELF1-1 and of pJC30 was cleaved with the restriction
20 enzymes *EcoRI* and *ScaI* (Pharmacia Biotech Europe GmbH, Freiburg, Germany). The restriction batches were then ligated together with the enzyme T4 DNA ligase (Roche Diagnostics GmbH, Mannheim, Germany) and transformed into the bacterial strain *Corynebacterium glutamicum* ATCC13032.
25 Selection was performed on LB agar containing 5 µg/ml of tetracycline. Plasmid DNA was reisolated from transformed colonies by an alkaline lysis method ("QIAGEN Plasmid Mini Handbook for Plasmid Mini Kit", Qiagen GmbH, Hilden, Germany, 1997). By restriction analysis of this plasmid DNA
30 and comparison with DNA fragments of known length, the

plasmid pSELF1-lysC was isolated, which consists of the plasmid vector pSELF1-1 and the lysC(FBR) gene region.

The plasmids pSELF-lysC and the control vector pSELF1-1 were transferred into the strain *Corynebacterium glutamicum* ATCC13032 by electroporation. Plasmid transfer was then proven by alkaline lysis and gel electrophoresis ("QIAGEN Plasmid Mini Handbook for Plasmid Mini Kit", Qiagen GmbH, Hilden, Germany, 1997). The strains ATCC13032 [pSELF1-1] and ATCC13032 [pSELF1-lysC] constructed in this manner were used for the production of lysine.

Both strains were initially cultured for 24 hours at 30°C in 50 ml of Luria-Bertani medium containing 5 µg/ml of tetracycline. 1 ml portions of culture were then washed twice in mineral medium (Bröer et al., Applied and Environmental Microbiology 59, 316-321 (1993)), transferred into 100 ml of mineral medium with 5 µg/ml of tetracycline and incubated for a further 24 hours at 30°C. 5 ml portions of culture supernatant were pelleted for 15 minutes at 13800xg and 4°C and sterile-filtered with a Millex-GS filter unit (0.22 µm, Millipore S.A., Molsheim, France). Lysine was determined in the filtered culture supernatants by means of HPLC analysis using the method of Büntemeyer et al. (Cytotechnology 5, 57-67 (1991)). The resultant lysine concentrations after 24 hours' culturing are summarised in Table 2.

Table 2

Lysine concentration in culture supernatants of various strains of *Corynebacterium glutamicum*.

Host	Plasmid	Lysine concentration (g / l)
ATCC13032	pSELF1-1	0.02
ATCC13032	pSELF1-lysC	1.0

5 Example 12

Production of pantothenic acid using pSELF3-1

In order to increase the copy number of a gene which is involved in the biosynthesis of pantothenate in coryneform bacteria, the panD gene from *Corynebacterium glutamicum* ATCC13032 was selected. The panD gene encodes the enzyme L-aspartate α -decarboxylase and was in cloned form on the plasmid vector pND10 (Dusch et al., Applied and Environmental Microbiology 65, 1530-1539 (1999)).

In order to clone the panD gene into the novel plasmid vector pSELF3-1 described in Example 9, plasmid DNA of pSELF3-1 was cleaved with the restriction enzymes SacI (Pharmacia Biotech Europe GmbH, Freiburg, Germany) and BstZ17I (New England Biolabs GmbH, Schwalbach, Germany) and plasmid DNA of pND10 was cleaved with the restriction enzymes SacI and ScaI (Pharmacia Biotech Europe GmbH, Freiburg, Germany) in accordance with the manufacturer's instructions. The restriction batches were then ligated together with the enzyme T4 DNA ligase in accordance with the manufacturer's instructions (Roche Diagnostics GmbH,

Mannheim, Germany) and transformed into the bacterial strain *Corynebacterium glutamicum* ATCC13032. Selection was performed on LB agar containing 5 µg/ml of tetracycline. Plasmid DNA was reisolated from the transformed colonies by
5 alkaline lysis ("QIAGEN Plasmid Mini Handbook for Plasmid Mini Kit", Qiagen GmbH, Hilden, Germany, 1997). By restriction analysis of the isolated plasmid DNA and comparison with DNA fragments of known length (DNA Molecular Weight Marker X, Roche Diagnostics GmbH,
10 Mannheim, Germany), the plasmid pSELF3-panD was isolated, which consists of the plasmid vector pSELF3-1 and the region of pND10 which encodes the panD gene.

In order to analyse pantothenate production in coryneform bacteria, the constructed plasmid vector pSELF3-panD and
15 the control vector pSELF3-1 were transferred into strain ATCC13032ΔilvA (Sahm et al., Applied and Environmental Microbiology 65, 1973-1979 (1999)). The presence of the plasmids was then proven by alkaline lysis ("QIAGEN Plasmid Mini Handbook for Plasmid Mini Kit", Qiagen GmbH, Hilden,
20 Germany, 1997). The strains ATCC13032ΔilvA [pSELF3-1] and ATCC13032ΔilvA [pSELF3-panD] constructed in this manner were used for the production of pantothenate.

The bacterial strains were initially cultured for 24 hours at 30°C in 50 ml of Luria-Bertani medium containing 5 µg/ml
25 of tetracycline. 1 ml portions of the bacterial culture were then washed twice with CGXII medium (Keilhauer et al., Journal of Bacteriology 175, 5595-5603, (1993)), to which 2 mM of isoleucine (Sigma-Aldrich Chemie GmbH, Deisenhofen, Germany) had been added, were transferred into 50 ml of
30 CGXII medium with 2 mM of isoleucine and 5 µg/ml of tetracycline and cultured for 24 hours at 30°C. A further 50 ml of CGXII medium containing 2 mM of isoleucine were inoculated with 3 ml of this culture. After further

incubation of the batch for 24 hours at 30°C, 20 ml of the bacterial culture were pelletised for 10 minutes at 1250xg. The culture supernatant was then sterile-filtered with a Millex-GS filter unit (0.22 µm, Millipore S.A., Molsheim, France). Pantothenate concentration was determined in the filtered culture supernatants in accordance with the instructions in the Difco Manual, 10th Edition (Difco Laboratories, Detroit, Michigan, USA). The resultant pantothenate concentrations after 24 hours' culturing are summarised in Table 3.

Table 3

Pantothenate concentration in culture supernatants of various strains of *Corynebacterium glutamicum*.

Host	Plasmid	Pantothenate concentration (ng/ml)
ATCC13032AilvA	pSELF3-1	14.1
ATCC13032AilvA	pSELF3-panD	54.1

The constructed plasmid vector pSELF3-panD was also used further to improve strain ATCC13032AilvA [pEKEx2panBC, pECM3ilvBNCD] (Sahm et al., Applied and Environmental Microbiology 65, 1973-1979 (1999)). This strain already bears the genes ilvBNCD and panBC, which have an advantageous effect on pantothenate biosynthesis, on known plasmid vectors.

Plasmid vector pSELF3-panD and the control vector pSELF3-1 were transferred by electroporation into strain ATCC13032A ilvA [pEKEx2panBC, pECM3ilvBNCD] (Sahm et al., Applied and Environmental Microbiology 65, 1973-1979 (1999)). Selection

was performed on LB agar containing 5 µg/ml of tetracycline. The presence of the transferred plasmid vectors and the plasmids already present in the bacterial strain was then proven by alkaline lysis ("QIAGEN Plasmid Mini Handbook for Plasmid Mini Kit", Qiagen GmbH, Hilden, Germany, 1997). Both the strains constructed in this manner were also used in the manner described above for the production of pantothenate. The resultant pantothenate concentrations in the culture supernatants after 24 hours' culturing are shown in Table 4.

Table 4

Pantothenate concentration in culture supernatants of various strains of *Corynebacterium glutamicum*.

Host	Plasmids	Pantothenate concentration (ng/ml)
ATCC13032ΔilvA	pECM3ilvBNCD pEKEx2panBC pSELF3-1	18.3
ATCC13032ΔilvA	pECM3ilvBNCD pEKEx2panBC pSELF3-panD	655.2

SEQUENCE LISTING

<110> Degussa-Hüls AG

5 <120> Novel plasmids from *Corynebacterium glutamicum* and use thereof

<130> 990111 BT

<140>

10 <141>

<160> 10

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 4539

<212> DNA

<213> *Corynebacterium glutamicum* LP-6

20

<220>

<221> CDS

<222> (228) .. (824)

<223> para

25

<220>

<221> CDS

<222> (1829) .. (3295)

<223> repA

30

<400> 1

cctaggetta gatgtgctgt cataattttc gccctcccg tcagacattt ggacatggat 60

ctcgggaaag attaagcggg ggaacttgaa ataattccac tttaaactag gaaatagcag 120

35

gtcaaagcga tatgttaagg cgtataaca tgagtatgtt atagcgttaa aacacacaac 180

atacttatgt tatgcagcta agacggaagt atgtcagact gataatc atg tcc ata 236
Met Ser Ile

40

ctg act atc gct cac aca aaa ggc ggc gtg gga aaa acg acc tct gca 284
Leu Thr Ile Ala His Thr Lys Gly Gly Val Gly Lys Thr Thr Ser Ala
5 10 15

45

gtg ctt ttg tgt gca gct gcc cac gcc cgc gga cta gcc gtt acc ctc 332
Val Leu Leu Cys Ala Ala His Ala Arg Gly Leu Ala Val Thr Leu
20 25 30 35

50

att gac tcc gac gct cag ggc acc gcc acc gcc tgg gcc cac gct gcc 380
Ile Asp Ser Asp Ala Gln Gly Thr Ala Thr Ala Trp Ala His Ala Ala
40 45 50

55

gaa gaa gcc ggt gat act ttc cgc tgg cct atc atc aca gcg gcc acg 428
Glu Glu Ala Gly Asp Thr Phe Pro Trp Pro Ile Ile Thr Ala Ala Thr
55 60 65

cct gcc cac ctt gcc cga acg ctc gac ggc cat aac gga ctc gtc atc 476
 Pro Ala His Leu Ala Arg Thr Leu Asp Gly His Asn Gly Leu Val Ile
 70 75 80

5 gtt gat acc ccg ccc ggt ggc tac gaa gtg atc gag acc gcc atc gaa 524
 Val Asp Thr Pro Pro Gly Gly Tyr Glu Val Ile Glu Thr Ala Ile Glu
 85 90 95

10 gca ggc gac ctc atc ctg atc ccc acc tct gcc tcc ccg cta gac atc 572
 Ala Gly Asp Leu Ile Leu Ile Pro Thr Ser Ala Ser Pro Leu Asp Ile
 100 105 110 115

15 aat cga gtc tgg cca act gtt gag gcc acc agt cac aag ccc gcc gta 620
 Asn Arg Val Trp Pro Thr Val Glu Ala Thr Ser His Lys Pro Ala Val
 120 125 130

20 gtc tgt cta tcc cag atc gac tcc cgc acc acc ttg ccc aag att gcc 668
 Val Cys Leu Ser Gln Ile Asp Ser Arg Thr Thr Leu Pro Lys Ile Ala
 135 140 145

25 cgt acc gca ctt gaa aac gaa ggc gtc gtc gtc gct gaa acg gag atc 716
 Arg Thr Ala Leu Glu Asn Glu Gly Val Val Val Ala Glu Thr Glu Ile
 150 155 160

ccc gcc cga gaa gcg tta aga cat atg tat gct aca act cca caa cgt 764
 Pro Ala Arg Glu Ala Leu Arg His Met Tyr Ala Thr Thr Pro Gln Arg
 165 170 175

30 tta tat ggc tac gat gaa cta ctt act gaa cta ctg tcc tca aac ctg 812
 Leu Tyr Gly Tyr Asp Glu Leu Leu Thr Glu Leu Ser Ser Asn Leu
 180 185 190 195

35 ttg gga gaa cat taatggetga tttatccaag aagctggcga aagcgccggt 864
 Leu Gly Glu His

taccagcgcg ccgcaaaaga aagtggccga gacctttact accgccacgg agaagccac 924
 ccgcaccacc atttaccctc caacaagtct cgctaagcgc cttaagcatg ctgccttga 984

40 agaggagcgc agtgtctctg caatctctgc aggactggcc gaagactggc taaacaaaga 1044
 agacgactaa gtatgtttat atgtcatggc atacgacata caaacataac aacatagaaa 1104

45 cctaacaacg tattaactcc aagtagtcag cgctgggagac catgccccat cgacacgcgg 1164
 ctgcgctgct cgtggggcca gaagtggcgc aggactgatg aaagaaaccc acaagacggt 1224
 taagcgctcaa agcgtcaagc ggacacaaca tgaaaacatc aagacgttta gacccttgog 1284

50 gcctttgacg ccagtcccg cgaacttat acattcgacg caatctatga agagatttaa 1344
 ggaatgaagg agacggcttt aatgtcacca gcacggcgca gttcaagaac cactaccgga 1404

55 cgaaaaacaa cagcccccct ggcggaaca cccacaccga ccgacgagga aggcacagag 1464
 cttaccggcg gtacaacat ttacctcaa gaggaacat ggaaatccat gaagcgcatg 1524
 accgtagaaa caggagaag cgtttctgcy tacatcgac gactcattga taagatgta 1584

60 aagcgctgct agaaaaagtt actccaaaac cccaatcgc tataacacga aaacataaca 1644
 acgttatagc gctttagcac taaactgtat cggggcgagt taaaaacttt tcgtgtcgca 1704

ggcacagagc aatcacactc gtgttactct ggtcgaaaac cttataaatg catgaagtc 1764

5 gccagggttg cacccttgac ggacttcgct atcaccgga ggacaccgg gggaagcac 1824

gtca atg agc tta cct tca aaa gga cga tca agc aca cct aca ggt gtg 1873
Met Ser Leu Pro Ser Lys Gly Arg Ser Ser Thr Pro Thr Gly Val
200 205 210

10 cgt gtt gcc caa cca ctg ccc acc cac cgc gac act ggc ggc ctg gac 1921
Arg Val Ala Gln Pro Leu Pro Thr His Arg Asp Thr Gly Gly Leu Asp
215 220 225 230

15 gac acc ccg gca gga ttc act gat cgt gat gca ctt ata gat cat ctc 1969
Asp Thr Pro Ala Gly Phe Thr Asp Arg Asp Ala Leu Ile Asp His Leu
235 240 245

20 ggg cgt aaa gca atc cac gga agc aaa gac cgt gac ttc ggc aaa gct 2017
Gly Arg Lys Ala Ile His Gly Ser Lys Asp Arg Asp Phe Gly Lys Ala
250 255 260

25 tat tac cgc cac gag gac ggt act ctt cgc ccg cgc ttg tat cgc gtg 2065
Tyr Tyr Arg His Glu Asp Gly Thr Leu Arg Pro Arg Leu Tyr Arg Val
265 270 275

gat tct gag cgc ttg aca cgc tgc cag tac gtc atg ctc acc acg cag 2113
Asp Ser Glu Ala Leu Thr Arg Cys Gln Tyr Val Met Leu Thr Thr Gln
280 285 290

30 caa tac gcc gct gta tta gtg gtc gat att gac cag ccc ggc caa tcg 2161
Gln Tyr Ala Ala Val Leu Val Val Asp Ile Asp Gln Pro Gly Gln Ser
295 300 305 310

35 gga ggg cac cca gcg aac tta tcg cct gag gtt cgt cag aag atg gcc 2209
Gly Gly His Pro Ala Asn Leu Ser Pro Glu Val Arg Gln Lys Met Ala
315 320 325

40 gct ctt atc gag cac aac ctt ggg ccg tcg tgg gtg ggc att aat ccc 2257
Ala Leu Ile Glu His Asn Leu Gly Pro Ser Trp Val Gly Ile Asn Pro
330 335 340

45 caa aac ggt aaa gca cag gcg atc tgg ttg att gat ccg gtg tac gca 2305
Gln Asn Gly Lys Ala Gln Ala Ile Trp Leu Ile Asp Pro Val Tyr Ala
345 350 355

gac aaa agc ggc aaa tct cgg cat atg agt ctg ctt gcc gcg acg agc 2353
Asp Lys Ser Gly Lys Ser Arg His Met Ser Leu Leu Ala Ala Thr Ser
360 365 370

50 cgt gct ttg ggt gag ctg ttg gat cat gat ccg aat ttc tct cac cgt 2401
Arg Ala Leu Gly Glu Leu Leu Asp His Asp Pro Asn Phe Ser His Arg
375 380 385 390

	ttt agt cgg agc cgg ttt tat gac ggc aac gac cct acc gcc tat cgt	2449
	Phe Ser Arg Ser Pro Phe Tyr Asp Gly Asn Asp Pro Thr Ala Tyr Arg	
	395 400 405	
5	tgg tat tgc cag cac aaa cac gtg cgc cgg tta gct gat ctt ctt aag	2497
	Trp Tyr Cys Gln His Lys His Val Arg Arg Leu Ala Asp Leu Leu Lys	
	410 415 420	
10	gag ata cgc act atg acg ggt caa gag cag tac acc aag cct cag caa	2545
	Glu Ile Arg Thr Met Thr Gly Gln Glu Gln Tyr Thr Lys Pro Gln Gln	
	425 430 435	
15	cag ttt tct agt ggc cgc gag ctt att aat gct gtg aaa act cgc aga	2593
	Gln Phe Ser Ser Gly Arg Glu Leu Ile Asn Ala Val Lys Thr Arg Arg	
	440 445 450	
20	gaa gaa gcc caa gca ttt aaa gca ctt gcc cag gac gtc gag acc gaa	2641
	Glu Glu Ala Gln Ala Phe Lys Ala Leu Ala Gln Asp Val Glu Thr Glu	
	455 460 465 470	
25	ctc agc aca gag ctt gat cag tac gac cgg gaa ctt atc gaa ggg gta	2689
	Leu Ser Thr Glu Leu Asp Gln Tyr Asp Pro Glu Leu Ile Glu Gly Val	
	475 480 485	
30	cga gtc tta tgg att agc cag ggg cgt gct gcc cgg gat gag acg gcg	2737
	Arg Val Leu Trp Trp Ile Ser Gln Gly Arg Ala Ala Arg Asp Glu Thr Ala	
	490 495 500	
35	ttt cgt tac gct ttg aaa acc tgc cac cgg cta cgg gcc gca ggt gag	2785
	Phe Arg Tyr Ala Leu Lys Thr Cys His Arg Leu Arg Ala Ala Gly Glu	
	505 510 515	
40	cgt atg act gat gcc gcg atc att gat gcc tat gag cat gcg tat aac	2833
	Arg Met Thr Asp Ala Ala Ile Ile Asp Ala Tyr Glu His Ala Tyr Asn	
	520 525 530	
45	gtt gct cag cgc cat ggg gga gac ggc cgg gat agt gag atg ccg ccg	2881
	Val Ala Gln Arg His Gly Gly Asp Gly Arg Asp Ser Glu Met Pro Pro	
	535 540 545 550	
50	atg cgg gat cgc cag acg atg gcg cgt cgc gtg cgc gcc tac gtg act	2929
	Met Arg Asp Arg Gln Thr Met Ala Arg Arg Val Arg Gly Tyr Val Thr	
	555 560 565	
55	caa tct aag acc agt atg ggc gca tca gcc cct cca ggg cgt gct aca	2977
	Gln Ser Lys Thr Ser Met Gly Ala Ser Ala Pro Pro Gly Arg Ala Thr	
	570 575 580	
60	agc act gaa cgt aaa gca tta tcc acg atg ggg cgt cga ggc ggt aaa	3025
	Ser Thr Glu Arg Lys Ala Leu Ser Thr Met Gly Arg Arg Gly Gly Lys	
	585 590 595	
65	aag gcc gca gaa cgc tgg aaa gac cgt gag agc cat tac gcg caa act	3073
	Lys Ala Ala Glu Arg Trp Lys Asp Arg Glu Ser His Tyr Ala Gln Thr	
	600 605 610	

gaa ttg gaa aag ctt gcc gat gcc agt aag aag cgt tca aga aaa gcc 3121
 Glu Leu Glu Lys Leu Ala Asp Ala Ser Lys Lys Arg Ser Arg Lys Ala
 615 620 625 630

5 aaa ggc acg cgc tta act att gcg ggc tgg gtg atg agt gtg gaa tct 3169
 Lys Gly Thr Arg Leu Thr Ile Ala Gly Trp Val Met Ser Val Glu Ser
 635 640 645

10 gag aca ggt gca tgg cct act atc gct gag gcg atg gtg gag ttt tcg 3217
 Glu Thr Gly Ala Trp Pro Thr Ile Ala Glu Ala Met Val Glu Phe Ser
 650 655 660

15 gtc tct aga gag act gta aaa agg gcg ctt aga tct gct gga att gag 3265
 Val Ser Arg Glu Thr Val Lys Arg Ala Leu Arg Ser Ala Gly Ile Glu
 665 670 675

20 ctt cca cgg ggc aga cga aag acc tca aat taaatggctc acttcgtaag 3315
 Leu Pro Arg Gly Arg Lys Thr Ser Asn
 680 685

25 caatatacgg ttccccgtgc acagcacggg ggggottaac tcttgcctct ttaagcttta 3375
 attaaatagt tcaggttata agcaatatatc ggttttccgt gtcttctgca gggaggccac 3435
 tttacttcgg cctttgaaag tgaattgtgt ttcaaattaa aggtgcttct gaagaccttt 3495
 aatctctagg gagtttttct gtaggaggca gttgggtcta gccagggttg ataagtgatt 3555

30 tcagtgagtg tccttctaga atgaaaagct tacgagtcgt ttaggcatat aacgggtgac 3615
 tagcgagttc agactttaaa agcgcaaaca aatttaatga ggtaagtcta tgagaaacgt 3675
 tcttttaact tgtccaatcc gtggcgagct tactgctact tcccttgctt ctgatgggct 3735

35 tacgcctacc gaagaggcga tgaggattga tttgcttgag tttcttatag ataaacgtga 3795
 ctaccacaaa gattttattg atgttgaaac tgtgggtgctg agcaatatcg gtaatgcagg 3855

40 gcgcaatagt ctctgtcgcg acgtcattgt gtatgacatc cogaagatgc aagcacgggc 3915
 catgtcacat gaagaacgac taattcatgc gacgttgatc gcagagggtga aacgagaggg 3975
 gaaatacaga aaaagcgctg tttctcatca gttagttccg gcattgaagc tcgctccatc 4035

45 tatgaagaca cttggaattt actgggataa cgaggaaagg ctctctcttc agaagacttt 4095
 ttcagatgaa atgcttttcg ttgaagagat caccgttgca aaactcccaa agtgggggtt 4155

50 ttccctcaca ggaaccccc tcaattacaa tcaactttcc totcogaaag atttgttcaa 4215
 aactctaagt ggtgtcgctg acattatgcg gagtgggtgga gtcgaagata aacaactcg 4275

55 ctatatogaa acagtcaagt tgcttctgc taggtataca gatgaacgca gtgcttctga 4335
 tccacaagat aaaaacggcg gagtctctgt gatgcagatt ttgtctgacg gtgaccctaa 4395
 ctttcgaaac cgaatggatg atctctataa gcgttcagcc gcgcgttaca gcaaaacgaa 4455

60 gactctattc gcgaataaga cgtcacagct tgatgatgcc acgctccgct aattagtggt 4515
 aaagattcaa ggttttcggt taac 4539

<210> 2
 <211> 199
 <212> ParA(pTET3)-PRT
 5 <213> Corynebacterium glutamicum LP-6

 <400> 2
 Met Ser Ile Leu Thr Ile Ala His Thr Lys Gly Gly Val Gly Lys Thr
 1 5 10 15
 10 Thr Ser Ala Val Leu Leu Cys Ala Ala Ala His Ala Arg Gly Leu Ala
 20 25 30
 Val Thr Leu Ile Asp Ser Asp Ala Gln Gly Thr Ala Thr Ala Trp Ala
 15 35 40 45
 His Ala Ala Glu Glu Ala Gly Asp Thr Phe Pro Trp Pro Ile Ile Thr
 50 55 60
 20 Ala Ala Thr Pro Ala His Leu Ala Arg Thr Leu Asp Gly His Asn Gly
 65 70 75 80
 Leu Val Ile Val Asp Thr Pro Pro Gly Gly Tyr Glu Val Ile Glu Thr
 85 90 95
 25 Ala Ile Glu Ala Gly Asp Leu Ile Leu Ile Pro Thr Ser Ala Ser Pro
 100 105 110
 Leu Asp Ile Asn Arg Val Trp Pro Thr Val Glu Ala Thr Ser His Lys
 115 120 125
 30 Pro Ala Val Val Cys Leu Ser Gln Ile Asp Ser Arg Thr Thr Leu Pro
 130 135 140
 Lys Ile Ala Arg Thr Ala Leu Glu Asn Glu Gly Val Val Val Ala Glu
 145 150 155 160
 Thr Glu Ile Pro Ala Arg Glu Ala Leu Arg His Met Tyr Ala Thr Thr
 165 170 175
 40 Pro Gln Arg Leu Tyr Gly Tyr Asp Glu Leu Leu Thr Glu Leu Leu Ser
 180 185 190
 Ser Asn Leu Leu Gly Glu His
 195

 <210> 3
 <211> 489
 50 <212> RepA(pTET3)-PRT
 <213> Corynebacterium glutamicum LP-6

 <400> 3
 Met Ser Leu Pro Ser Lys Gly Arg Ser Ser Thr Pro Thr Gly Val Arg
 1 5 10 15
 Val Ala Gln Pro Leu Pro Thr His Arg Asp Thr Gly Gly Leu Asp Asp
 20 25 30
 60 Thr Pro Ala Gly Phe Thr Asp Arg Asp Ala Leu Ile Asp His Leu Gly
 35 40 45
 Arg Lys Ala Ile His Gly Ser Lys Asp Arg Asp Phe Gly Lys Ala Tyr

	50	55	60
	Tyr Arg His Glu Asp Gly Thr Leu Arg Pro Arg Leu Tyr Arg Val Asp		
	65	70	75 80
5	Ser Glu Ala Leu Thr Arg Cys Gln Tyr Val Met Leu Thr Thr Gln Gln		
		85	90 95
10	Tyr Ala Ala Val Leu Val Val Asp Ile Asp Gln Pro Gly Gln Ser Gly		
		100	105 110
	Gly His Pro Ala Asn Leu Ser Pro Glu Val Arg Gln Lys Met Ala Ala		
		115	120 125
15	Leu Ile Glu His Asn Leu Gly Pro Ser Trp Val Gly Ile Asn Pro Gln		
		130	135 140
	Asn Gly Lys Ala Gln Ala Ile Trp Leu Ile Asp Pro Val Tyr Ala Asp		
		145	150 155
20	Lys Ser Gly Lys Ser Arg His Met Ser Leu Leu Ala Ala Thr Ser Arg		
		165	170 175
	Ala Leu Gly Glu Leu Leu Asp His Asp Pro Asn Phe Ser His Arg Phe		
25		180	185 190
	Ser Arg Ser Pro Phe Tyr Asp Gly Asn Asp Pro Thr Ala Tyr Arg Trp		
		195	200 205
30	Tyr Cys Gln His Lys His Val Arg Arg Leu Ala Asp Leu Leu Lys Glu		
		210	215 220
	Ile Arg Thr Met Thr Gly Gln Glu Gln Tyr Thr Lys Pro Gln Gln Gln		
		225	230 235
35	Phe Ser Ser Gly Arg Glu Leu Ile Asn Ala Val Lys Thr Arg Arg Glu		
		245	250 255
	Glu Ala Gln Ala Phe Lys Ala Leu Ala Gln Asp Val Glu Thr Glu Leu		
40		260	265 270
	Ser Thr Glu Leu Asp Gln Tyr Asp Pro Glu Leu Ile Glu Gly Val Arg		
		275	280 285
45	Val Leu Trp Ile Ser Gln Gly Arg Ala Ala Arg Asp Glu Thr Ala Phe		
		290	295 300
	Arg Tyr Ala Leu Lys Thr Cys His Arg Leu Arg Ala Ala Gly Glu Arg		
		305	310 315 320

Met Thr Asp Ala Ala Ile Ile Asp Ala Tyr Glu His Ala Tyr Asn Val
325 330 335

5 Ala Gln Arg His Gly Gly Asp Gly Arg Asp Ser Glu Met Pro Pro Met
340 345 350

Arg Asp Arg Gln Thr Met Ala Arg Arg Val Arg Gly Tyr Val Thr Gln
355 360 365

10 Ser Lys Thr Ser Met Gly Ala Ser Ala Pro Pro Gly Arg Ala Thr Ser
370 375 380

Thr Glu Arg Lys Ala Leu Ser Thr Met Gly Arg Arg Gly Gly Lys Lys
385 390 395 400

15 Ala Ala Glu Arg Trp Lys Asp Arg Glu Ser His Tyr Ala Gln Thr Glu
405 410 415

20 Leu Glu Lys Leu Ala Asp Ala Ser Lys Lys Arg Ser Arg Lys Ala Lys
420 425 430

Gly Thr Arg Leu Thr Ile Ala Gly Trp Val Met Ser Val Glu Ser Glu
435 440 445

25 Thr Gly Ala Trp Pro Thr Ile Ala Glu Ala Met Val Glu Phe Ser Val
450 455 460

Ser Arg Glu Thr Val Lys Arg Ala Leu Arg Ser Ala Gly Ile Glu Leu
465 470 475 480

30 Pro Arg Gly Arg Arg Lys Thr Ser Asn
485

35

<210> 4
<211> 1856
<212> DNA
40 <213> *Corynebacterium glutamicum* LP-6

<220>
<221> CDS
<222> (338)..(1291)
45 <223> repA

<400> 4
gcatgccaat aaaagtcacac ccgccgtggc caccacaaac cagagtgtaa ataacattg 60

50 agatagcttg atacctagac atctttccgc ctgataccta gacattaaga cgtctagatt 120

gcttgcctatc tacaaccctc caccagggga ctaaattaat attcoaaca agaaggactc 180

ccatgttttc gtattctaaa tatcgaaatc ctgatcggcg ttctgggcag ctatgtcac 240

55 tgtgactgct acgatcaggg gaaaattaaa agacctggca ctgcgcgcaa cagtccaggt 300

catgacccca cactatttct aagagacatg agggattt atg gat gat cat act ctg 355
Met Asp Asp His Thr Leu
1 5

5 cca cag cca gat tcg ggc aac tca gat cca att agc gat ttg gaa gcg 403
Pro Gln Pro Asp Ser Gly Asn Ser Asp Pro Ile Ser Asp Leu Glu Ala
10

10 cgc ctc gca gag atc gag gct ggc ctc ggc gat ccg ctc agt ttc acg 451
Arg Leu Ala Glu Ile Glu Ala Gly Leu Gly Asp Pro Leu Ser Phe Thr
25 30 35

15 tca aaa acc ctg atc cag gca act ttt cca cac agt gca aaa gcc gga 499
Ser Lys Thr Leu Ile Gln Ala Thr Phe Pro His Ser Ala Lys Ala Gly
40 45 50

20 aaa gaa ctt gtc ctg gtt aac ggc cat acg aca gtc acg atg tac agc 547
Lys Glu Leu Val Leu Val Asn Gly His Thr Thr Val Thr Met Tyr Ser
55 60 65 70

25 cgc cac ggc ctg cca tat ggc tca tgg cca ccg ctc att atg tgc tgg 595
Arg His Gly Leu Pro Tyr Gly Ser Trp Pro Arg Leu Ile Met Cys Trp
75 80 85

30 cta aca agg gaa gcc ctt cgc cgc caa aat ctc cca att gat gag gct 643
Leu Thr Arg Glu Ala Leu Arg Arg Gln Asn Leu Pro Ile Asp Glu Ala
90 95 100

35 cgt gaa atc ccg ctt aat tca agc ttg agt ggt ttt atg ccg gaa gtt 691
Arg Glu Ile Pro Leu Asn Ser Ser Leu Ser Gly Phe Met Arg Glu Val
105 110 115

40 ggc atc gga cgt gca acc gga ggg gag cgt ggc acg atc acc gcg ctg 739
Gly Ile Gly Arg Ala Thr Gly Gly Glu Arg Gly Thr Ile Thr Ala Leu
120 125 130

45 aaa aag cag atg cgg tct ctt ttc tcc act tca atc ggc att gac atc 787
Lys Lys Gln Met Arg Ser Leu Phe Ser Thr Ser Ile Gly Ile Asp Ile
135 140 145 150

50 aaa gga gat gac gac ctt aag ctc ctg gat ctt gat gaa tca gtt atc 835
Lys Gly Asp Asp Asp Leu Lys Leu Leu Asp Leu Asp Glu Ser Val Ile
155 160 165

55 gct gag cgg acg gag atg tgg tgg acg ccg cga ccc cac gat gac atc 883
Ala Glu Arg Thr Glu Met Trp Trp Thr Pro Arg Pro His Asp Asp Ile
170 175 180

gat ttt gag gga tat att cga ctc tcc gct act ttc tac tca gat ctc 931
Asp Phe Glu Gly Tyr Ile Arg Leu Ser Ala Thr Phe Tyr Ser Asp Leu
185 190 195

atc aaa tca gcc gtc ccc ctc gac acc cga atc ctc cgc agt cta aag 979
Ile Lys Ser Ala Val Pro Leu Asp Thr Arg Ile Leu Arg Ser Leu Lys
200 205 210

His Ser Ala Lys Ala Gly Lys Glu Leu Val Leu Val Asn Gly His Thr
 50 55 60
 5 Thr Val Thr Met Tyr Ser Arg His Gly Leu Pro Tyr Gly Ser Trp Pro
 65 70 75 80
 Arg Leu Ile Met Cys Trp Leu Thr Arg Glu Ala Leu Arg Arg Gln Asn
 85 90 95
 10 Leu Pro Ile Asp Glu Ala Arg Glu Ile Pro Leu Asn Ser Ser Leu Ser
 100 105 110
 Gly Phe Met Arg Glu Val Gly Ile Gly Arg Ala Thr Gly Gly Glu Arg
 115 120 125
 15 Gly Thr Ile Thr Ala Leu Lys Lys Gln Met Arg Ser Leu Phe Ser Thr
 130 135 140
 20 Ser Ile Gly Ile Asp Ile Lys Gly Asp Asp Asp Leu Lys Leu Leu Asp
 145 150 155 160
 Leu Asp Glu Ser Val Ile Ala Glu Arg Thr Glu Met Trp Trp Thr Pro
 165 170 175
 25 Arg Pro His Asp Asp Ile Asp Phe Glu Gly Tyr Ile Arg Leu Ser Ala
 180 185 190
 Thr Phe Tyr Ser Asp Leu Ile Lys Ser Ala Val Pro Leu Asp Thr Arg
 195 200 205
 30 Ile Leu Arg Ser Leu Lys Lys Ser Pro Met Ala Ile Asp Val Tyr Ser
 210 215 220
 Trp Leu Thr Tyr Arg Val Ser Tyr Leu Arg Tyr Pro Thr Val Ile Lys
 225 230 235 240
 35 Trp Asp Gln Ile Gln Gly Gln Leu Gly Ala Gly Tyr Pro Asp Thr Ser
 245 250 255
 40 Gln Gly Met Arg Asn Phe Arg Lys Lys Phe Leu Ile Ala Leu Asn Lys
 260 265 270
 Val Ile Asp Val Trp Pro Thr Asp Ser Ile Ser Ile Val Lys Asn Gly
 275 280 285
 45 Ile Leu Leu Thr Pro Gly Ser Pro Ser Val Pro Arg Arg Ala Gln Asp
 290 295 300
 50 Glu Phe Gln Lys Arg Phe Ser Ile Gly Asp Asp Pro Leu Phe
 305 310 315

 55 <210> 6
 <211> 7316
 <212> DNA
 <213> Corynebacterium glutamicum LP-6

 60 <220>
 <221> gene
 <222> Complement((1447)..(2013))
 <223> tetR

```

<220>
<221> CDS
<222> (2124)..(3272)
<223> tetA
5
<220>
<221> CDS
<222> (5882)..(6718)
<223> aadA
10
<400> 6
aagcttgagc atgcttggcg gagattggac ggaagggaacg atgacggatt tcaagtggcg 60
ccatttccag ggtgatgtga tcctgtggcg ggtgcgctgg tattgtcgct atccgatcac 120
15
ctatcgcgac cttgaggaaa tgctggcgga acgcggcatt tcggtcgacc atacgacgat 180
ctatcgctgg gtccagtgtc acgccccgga gatggagaag cggtcgctgt ggttctggcg 240
20
cgctggcctt gatccgagct ggcgcctgga tgaacctac gtcaagggtgc ggggcaagtgc 300
gacctacctg tacggggcag tcgacaagcg gggcgacacg atcgatttct acctgtcgcc 360
gacccgcagc gccaaaggcag cgaagcgggt cctgggcaag gccctgcgag gcctgaagca 420
25
ctgggaaaag cctgccacgc tcaataccga caaagcgccg agctatgggt cagcgatcac 480
cgaattgaag cgcgaaggaa agctggacgc ggagacggcc caccggcagg tgaagtatct 540
30
caataacgtg atcgaggccg atcacggaaa gctcaagata ctgatcaagc cgggtgcgcgg 600
tttcaaatcg atccccacg cctatgccac gatcaaggga ttccaagtca tgcgagccct 660
gcgcaaaagg caggetcgcc cctgggtgct gcagcccgcc atcaggggcg aggtgcgcct 720
35
tgtggagaga gcttttggca ttgggccttc ggcgctgacg gaggccatgg gcattgctcaa 780
ccaccatttc gcagcagcgc cctgatcggc gcagagcgac agcctacctc tgactgcgcg 840
40
caatcttttc aacagagcct ttgcgtcaat gcaggggagat agcgaagagc gcgcttcaac 900
ggagatgctc gaatgggtcc acgacggatt ggagtccgtg gtgcggcgag acgtagatga 960
ttcgcacgcc gtaccctgct gcgcgcgctg gctcggggtc gcattctcgcg cggcagacgt 1020
45
tacagagcgc gtgctcgttg ctccccaga ccgtgacctc gatatcgctg gggatctcca 1080
ttccgtcgaa ctccatatgc ggaggttagc tgcgcgggat tgagtcgtgt caagatgcgg 1140
50
caccgatgct aaaccccgct tacctatggg catcgcgccg gtgcgcgaact cgacgcttag 1200
ttcttgaggt actcaggac gccgatgacg cgcttggttc ctgtgcgcct gttaaggctg 1260
agcatggtga agatgctgct gatgtccgtt tcgcgatcg cgacgcgaca tgcacacggt 1320
55
ccctgatttg ctgctttgtg agccccgtag ccatgagcga atcgtcagta tcgcggagga 1380
gggtgctcgg gagcgggaaa ggattgacct tactgacgca gagacccaaa gtgcgagcat 1440
60
ccctcatgct tttgatgcca gcccttcaac cattgcaact aaccgaact cgaatctag 1500
gtcttgatcg acaggctcac atcgttgtc gagcgctggt tgttcttcta gtacgaaacc 1560

```

gaccgtatag cggtgatag ccatgagagc tcggaccgca gagccctcag cgaatccttc 1620
ggacacgaga aactcgatct gactttcggg ggcacccgag cccgctggca tctggctact 1680
5 cttttgacgg tgaactctg cgtgcagcgg tgctccatcc cggactgcca gaagcgtgt 1740
ccggaagctc cgcgcgttgc gcaggagaaa gtgcgccag cgcctccctg actctgggag 1800
10 tgaggcgtgg tgttcgcat caagcacatc agctgcgagc gatccgagca ggtgggcctt 1860
tgtccgaaa tgccagtaga gcgctggctg ctgcaccgcg agatgcgcag ccagcgcccg 1920
tgtggtgaaa ccgtcgatcc ccgtgttatt gagcacatgc ctgcaccgcg gcaagactgc 1980
15 tgcacgatcg agtcgcgctt gtttctgagc catgcttgca ctttatcatc gataacttta 2040
tcgttgataa ggtgtcatct ctcacttccg ctctggtctc gttggccacg gtcctcatca 2100
20 cggctagcct cgacgcccgc gcc atg gcc ctg gtg atg ccg att ctt ccc gca 2153
Met Gly Leu Val Met Pro Ile Leu Pro Ala
1 5 10

25 ctg cta cac gag gca ggg gtc acc gct gat gcg gtt ccg ctg aac gtc 2201
Leu Leu His Glu Ala Gly Val Thr Ala Asp Ala Val Pro Leu Asn Val
15 20 25

30 gga gtg ctg atc gcg ctc tac gcg gta atg cag ttc atc ttt gcc ccc 2249
Gly Val Leu Ile Ala Leu Tyr Ala Val Met Gln Phe Ile Phe Ala Pro
30 35 40

35 gta ctg gga acg ctg tcg gac cga ttc gcc cgc cgc cgg gtg ctg ctt 2297
Val Leu Gly Thr Leu Ser Asp Arg Phe Gly Arg Arg Arg Val Leu Leu
45 50 55

40 gtt tcc ctg gcc ggt gcg acc gtc gac tat ctc ctg ctc gcc acg acg 2345
Val Ser Leu Ala Gly Ala Thr Val Asp Tyr Leu Val Leu Ala Thr Thr
60 65 70

45 tcc gct ctg tcg gtg ttc tat atc gcc cgc gca gtg gct ggg ata acc 2393
Ser Ala Leu Ser Val Phe Tyr Ile Ala Arg Ala Val Ala Gly Ile Thr
75 80 85 90

gga gcg acc aat gcg gtc acc gcc acc gtg atc gcc gac atc acg cca 2441
Gly Ala Thr Asn Ala Val Thr Ala Thr Val Ile Ala Asp Ile Thr Pro
95 100 105

	ccc cac cag cgc gcc aag cgt ttc ggt tta ctc agt gcc tgc tat ggc	2489
	Pro His Gln Arg Ala Lys Arg Phe Gly Leu Leu Ser Ala Cys Tyr Gly	
5	110 115 120	
	ggc gga atg atc gcg ggg cca gcc atg ggt gga ctg ttc ggt gcc atc	2537
	Gly Gly Met Ile Ala Gly Pro Ala Met Gly Gly Leu Phe Gly Ala Ile	
	125 130 135	
10	tcg cca cat ctg cgc ttt ttg ctc gct gct ctt ctc tca gcg agc aat	2585
	Ser Pro His Leu Pro Phe Leu Leu Ala Ala Leu Ser Ala Ser Asn	
	140 145 150	
15	ctg gca ctc acc ttt atc ctg tta cgc gag acc cgt cct gat tcc cct	2633
	Leu Ala Leu Thr Phe Ile Leu Leu Arg Glu Thr Arg Pro Asp Ser Pro	
	155 160 165 170	
	gcg cgc tct gcg tgc ctc gct cag cat cgt ggt cgc ccc ggc ctc agc	2681
20	Ala Arg Ser Ala Ser Leu Ala Gln His Arg Gly Arg Pro Gly Leu Ser	
	175 180 185	
	gcg gtg cct ggg att acc ttc cta tta atc gca ttc ggc ctt gtt caa	2729
	Ala Val Pro Gly Ile Thr Phe Leu Leu Ile Ala Phe Gly Leu Val Gln	
25	190 195 200	
	ttc att ggg cag gct cca ggt gcg acc tgg gtg ctg ttt act gaa cac	2777
	Phe Ile Gly Gln Ala Pro Gly Ala Thr Trp Val Leu Phe Thr Glu His	
	205 210 215	
30	cgc ctc gac tgg agt ccc gtc gaa gtt gga atc tcc ctg tcc gtt ttc	2825
	Arg Leu Asp Trp Ser Pro Val Glu Val Gly Ile Ser Leu Ser Val Phe	
	220 225 230	
35	ggg atc gta cag gtt ctc gtg cag gcc ctc ctt act ggc cgc atc gtg	2873
	Gly Ile Val Gln Val Leu Val Gln Ala Leu Leu Thr Gly Arg Ile Val	
	235 240 245 250	
	gag tgg atc ggt gag gca aaa aca gtc atc atc ggg tgt att acc gac	2921
40	Glu Trp Ile Gly Glu Ala Lys Thr Val Ile Ile Gly Cys Ile Thr Asp	
	255 260 265	
	gcc ttg ggt ctc gta ggc ctg gcg att gtc act gac gca ttt tcc atg	2969
	Ala Leu Gly Leu Val Gly Leu Ala Ile Val Thr Asp Ala Phe Ser Met	
45	270 275 280	
	gca cct atc ttg gcg gca ctg ggg atc ggt ggc atc ggc ctc ccc gct	3017
	Ala Pro Ile Leu Ala Ala Leu Gly Ile Gly Ile Gly Leu Pro Ala	
	285 290 295	
50	ctg caa acc ctt ctc tcc cag cgc gtc gat gaa cag cac caa ggg cgc	3065
	Leu Gln Thr Leu Leu Ser Gln Arg Val Asp Glu Gln His Gln Gly Arg	
	300 305 310	
55	ctc cag ggt gtg ctc gcc agc atc aac agc gtc aca tgc atc ttc gga	3113
	Leu Gln Gly Val Leu Ala Ser Ile Asn Ser Val Thr Ser Ile Phe Gly	
	315 320 325 330	

ccg gtc gct ttc aca acg atc ttc gcg ctc act tac atc aac gcc gac 3161
 Pro Val Ala Phe Thr Thr Ile Phe Ala Leu Thr Tyr Ile Asn Ala Asp 345
 5 ggc ttc ctc tgg ctc tgc gcc gca gca ctc tac gtg ccc tgc gtg att 3209
 Gly Phe Leu Trp Leu Cys Ala Ala Ala Leu Tyr Val Pro Cys Val Ile 350 355 360
 10 ctc atc atg cgt ggt aca gca gcg tcc cgg aag ttc ggc tct tgg gcg 3257
 Leu Ile Met Arg Gly Thr Ala Ala Ser Pro Lys Phe Gly Ser Trp Ala 365 370 375
 15 agc gcc gac tcg atg tgagtgtga gacgtgagca ggagcaacac gccggcgaca 3312
 Ser Gly Asp Ser Met 380
 ctgcttcgcc atggccgact agcgagacgg cgcacccggg aaactcggca tcatctacca 3372
 20 aggacaggtc agctggggagc ctgatagacc catcgaaatg tgcgtgcoga tcgcggagaa 3432
 gggccggggcg catcggatcg agccatagca ccatagtct tcacggaagt gcgtgcacgg 3492
 25 agacttggtt gtgaaccggg ccaagggaga gctggaggcc ctctccgagt ggcttgccga 3552
 tgacatgagc tggacgctca tcgagaaatc cacacacagc ggcctccagt cagcccgaga 3612
 ggtgcgccc cgttctccc gagcgggtgg aggtcatttc tgtgtcacc cacggacgac 3672
 30 gcgcttctcg cgacggctac ctcgaggctg gaggaatgcg cgtccgtttc agccatgcgt 3732
 tccgcttctg cagcaccccc aagacctoga tgatcgaga actgcgacgc tactgcatcg 3792
 agacgcagtg tgactgaggc ctgtgcggac agcacgaacg acccttgagc ccgtaatctg 3852
 35 ggaaccgcag aaactaccog atcgaaacgc aactactttg ccgaccctac ggggttggtt 3912
 cgcggtctgc gtccttggcc gggctctgtt gcaaaaaatc tgaagcttga gcattgcttg 3972
 40 cggagattgg acggacggaa cgatgacgga ttccaagtgg cgcatttcc agggatgatg 4032
 gatcctgtgg gcggtgcgct ggtattgtcg ctatccgac agctatccgc acctgagga 4092
 aatgctggcg gaacgcggca ttctggtcga ccatacgacg atctatcgct gggctccagt 4152
 45 ctacgcccc gagatggaga agcggctgcg ctggttctgg cggcgtggct ttgatccgag 4212
 ctggcgctg gatgaaacct acgtcaaggt gcggggcaag tggacctacc tgtaccgggc 4272
 50 agtcgacaag cggggcgaca cgatcgattt ctacctgtcg ccgaccgcga gcgccaaagg 4332
 agcgaagcgg ttcttgggca aggccctgcg aggcctgaag cactgggaaa agcctgccac 4392
 gctcaatacc gacaaagcgc cgagctatgg tgcagcgatc accgaattga agcgcgaagg 4452
 55 aaagctggac cgggagacgg cccaccgcga ggtgaagtat ctcaataacg tgatcgaggc 4512
 cgatcacgga aagctcaaga tactgatcaa gccgtgcgc ggtttcaaat cgatccccc 4572
 60 ggcctatgcc acgatcaagg gattcgaagt catgcgagcc ctgcgcaaaq gacaggctcg 4632
 cccctggtgc ctgcagcccc gcatcagggg cgaggtgcgc cttgtggaga gagcttttgg 4692

cattggggccc tcggcgctga cggaggccat gggcatgctc aaccaccatt tcgcagcagc 4752
 cgctgatgc gcgcagagcg acagcctacc tctgactgcc gccaatcttt gcaacagagc 4812
 5 cgctgtagag acgtcggaat ggcgcagcag atcctgcacg gttcgaatgt cgtaaccgct 4872
 gcggagcaag gcctgcgcga acgagtggcg gaggggtgctc ggttgggcgg gcttcgtgat 4932
 10 gcctgcttgt tctacggcac gtttgaaggc gcgctgaaag gtctggtcat acatgtgatg 4992
 gcgacgcacg acaccgctcc gtggatcggt cgaatcgctg tgctgcgcga aaaccagaaa 5052
 ccacggccag gaatgcccgg cgcgcggata ctcccgctca agggcgctcg gaagcgcaac 5112
 15 gccgctgcgg cctcggcct ggtccttcag ccaccatgcc cgtgcacgcg acagctgctc 5172
 gcgcaggctg ggtgccaaag tctcgggtaa catcaaggcc cgatccttgg agcccttgcc 5232
 ctcccgccag atgatcgtgc cgtgatcgaa atccagatcc ttgaccgcga gttgcaaaac 5292
 20 ctactgatc cgcgatcccg ttccatacag aagctggggc aacaaacgat gctcgctctc 5352
 cagaaaacgg aggatcgcaa ccacttcac cggggtcagc accaccggca agcgccgcga 5412
 25 cggccgaggt ctccgatct cctgaagcca ggcgagatcc gtgcacagca ccttgccgta 5472
 gaagaacacg aaggcgcgca atgcctgacg atgcgtggag accgaaacct tgcgtcgtt 5532
 cgccagccag gacagaaatg cctgcacttc gctgctgcc aaggttgccg ggtgacgcac 5592
 30 accgtggaag cggatgaagg cagcaaccca gtggacatcc gctgttccg ttcgtaagct 5652
 ataatgcaag tagcgtatgc gctcacgcaa ctggtccaga acctgaccg aacgcagcgg 5712
 35 tggtaacggt gcagtgtcgg ttttcatggc ttgttatgac tgtttgttg tacagtctat 5772
 gcctcggggc tccaagcagc aagcgcgtta cgcctggggt cgatgtttga tgttatggag 5832
 40 cagcaacgat gttacgcagc agggcagtcg ccctaaaaca aagttagac atg atg agc 5890
 Met Met Ser
 385
 aac tct ata cac acc gga atc tca aga cag ctt tca cag gca cgc gat 5938
 45 Asn Ser Ile His Thr Gly Ile Ser Arg Gln Leu Ser Gln Ala Arg Asp 400
 390 395
 gta att aaa cgc cat ttg gca tca acg ctg aaa gcc ata cac ttg tat 5986
 Val Ile Lys Arg His Leu Ala Ser Thr Leu Lys Ala Ile His Leu Tyr 415
 405 410
 50 ggt tct gca att gat ggt ggc ctc aaa cca tat agc gac att gat ctg 6034
 Gly Ser Ala Ile Asp Gly Gly Leu Lys Pro Tyr Ser Asp Ile Asp Leu 420 425 430

	ctg gtt acc gtg gat gca cgc ttg gat gaa gct acc aga cgc tcc ctg	6082
	Leu Val Thr Val Asp Ala Arg Leu Asp Glu Ala Thr Arg Arg Ser Leu	
	435 440 445 450	
5	atg ctc gat ttc ttg aat atc tcg gca cca cca tgc gaa agc tca ata	6130
	Met Leu Asp Phe Leu Asn Ile Ser Ala Pro Pro Cys Glu Ser Ser Ile	
	455 460 465	
10	ctc cgg ccg cta gag gta act gtt gtt gca tgc aac gaa gta gtg cct	6178
	Leu Arg Pro Leu Glu Val Thr Val Val Ala Cys Asn Glu Val Val Pro	
	470 475 480	
15	tgg cgt tat ccg gca cga cga gaa ctg cag ttc ggg gag tgg ctg cgg	6226
	Trp Arg Tyr Pro Ala Arg Arg Glu Leu Gln Phe Gly Glu Trp Leu Arg	
	485 490 495	
20	gag gat att ctt gaa ggt gtc ttc gag cca gcc gcc ttg gac gcc gac	6274
	Glu Asp Ile Leu Glu Gly Val Phe Glu Pro Ala Ala Leu Asp Ala Asp	
	500 505 510	
25	ctt gca att cta ata acg aaa gct agg caa cac agc atc gct tta gta	6322
	Leu Ala Ile Leu Ile Thr Lys Ala Arg Gln His Ser Ile Ala Leu Val	
	515 520 525 530	
	ggt cca gtg gct caa aaa gtc ttc atg ccg gtg cca gag cat gac ttt	6370
	Gly Pro Val Ala Gln Lys Val Phe Met Pro Val Pro Glu His Asp Phe	
	535 540 545	
30	ctc cag gtg ctt tcc gat acc ctt aag ctg tgg aat act cat gag gat	6418
	Leu Gln Val Leu Ser Asp Thr Leu Lys Leu Trp Asn Thr His Glu Asp	
	550 555 560	
35	tgg gaa aat gag gag cgg aac atc gta ctc acg tta gct cgg atc tgg	6466
	Trp Glu Asn Glu Glu Arg Asn Ile Val Leu Thr Leu Ala Arg Ile Trp	
	565 570 575	
40	tat agc act gaa act gga gga atc gtc ccc aag gat gtg gcc gcc gaa	6514
	Tyr Ser Thr Glu Thr Gly Gly Ile Val Pro Lys Asp Val Ala Ala Glu	
	580 585 590	
45	tgg gtt tta gag cgc ttg cca gct gag cat aag cca ata ctg gtt gag	6562
	Trp Val Leu Glu Arg Leu Pro Ala Glu His Lys Lys Pro Ile Leu Val Glu	
	595 600 605 610	
	gcg cgg caa gcc tat ctt ggg ctt tgc aag gat agt ctt gct ttg cgt	6610
	Ala Arg Gln Ala Tyr Leu Glu Leu Cys Lys Asp Ser Leu Ala Leu Arg	
	615 620 625	
50	gca gat gag act tcg gcg ttc att ggc tat gca aag tct gcg gtc gct	6658
	Ala Asp Glu Thr Ser Ala Phe Ile Gly Tyr Ala Lys Ser Ala Val Ala	
	630 635 640	
55	gat ttg ctc gaa aag cga aaa tct caa act tcg cat att tgc gat ggc	6706
	Asp Leu Leu Glu Lys Arg Lys Ser Gln Thr Ser His Ile Cys Asp Gly	
	645 650 655	

gcc aag aac gtc taacgtctaa ctattcattt aagccgaagc cgcttcgcgg 6758
 Ala Lys Asn Val
 660

5 ctcggccttaa ttcaggcggtt agatgcacta agcacataat tgctcacagc caaactatca 6818
 ggtcaagtct gcttttatta tttttaagcg tgcataataa gccctacaca aattgggaga 6878

10 tatatcatga aaggctggct tttcttctgt atcgcaatag ttggcgaagt aatcgcaaca 6938
 tccgcattaa aatctagcga gggctttact aagcttgccc ctctccgcgt tgcataaatc 6998
 ggttatggca tcgcatttta tttctttct ctggttctga aatccatccc tgcgttggtt 7058

15 gcttatgcag tctggtcggg actcggcgtc gtcataatta cagccattgc ctggttgctt 7118
 catgggcaaa agcttgatgc gtggggcttt gtaggtatgg ggctcataat tgcctgcctt 7178
 20 ttgctcgcgc gatcccatc gtggaagtcg ctgcggaggc cgaccgatg gtgacgggtg 7238
 tcggcattct gaatctcacc gaggactcct tcttcgatga gagccggcgg ctgagcccg 7298
 ccggcgctgt caccgcgg 7316

25 <210> 7
 <211> 383
 <212> TetA-PRT
 30 <213> Corynebacterium glutamicum LP-6

<400> 7
 Met Gly Leu Val Met Pro Ile Leu Pro Ala Leu Leu His Glu Ala Gly
 1 5 10 15

35 Val Thr Ala Asp Ala Val Pro Leu Asn Val Gly Val Leu Ile Ala Leu
 20 25 30

40 Tyr Ala Val Met Gln Phe Ile Phe Ala Pro Val Leu Gly Thr Leu Ser
 35 40 45

Asp Arg Phe Gly Arg Arg Arg Val Leu Leu Val Ser Leu Ala Gly Ala
 50 55 60

45 Thr Val Asp Tyr Leu Val Leu Ala Thr Thr Ser Ala Leu Ser Val Phe
 65 70 75 80

Tyr Ile Ala Arg Ala Val Ala Gly Ile Thr Gly Ala Thr Asn Ala Val
 85 90 95

50 Thr Ala Thr Val Ile Ala Asp Ile Thr Pro Pro His Gln Arg Ala Lys
 100 105 110

Arg Phe Gly Leu Leu Ser Ala Cys Tyr Gly Gly Gly Met Ile Ala Gly
 115 120 125

55 Pro Ala Met Gly Gly Leu Phe Gly Ala Ile Ser Pro His Leu Pro Phe
 130 135 140

60 Leu Leu Ala Ala Leu Leu Ser Ala Ser Asn Leu Ala Leu Thr Phe Ile
 145 150 155 160

Leu Leu Arg Glu Thr Arg Pro Asp Ser Pro Ala Arg Ser Ala Ser Leu

	165	170	175
	Ala Gln His Arg Gly Arg Pro Gly Leu Ser Ala Val Pro Gly Ile Thr		
	180	185	190
5	Phe Leu Leu Ile Ala Phe Gly Leu Val Gln Phe Ile Gly Gln Ala Pro		
	195	200	205
10	Gly Ala Thr Trp Val Leu Phe Thr Glu His Arg Leu Asp Trp Ser Pro		
	210	215	220
	Val Glu Val Gly Ile Ser Leu Ser Val Phe Gly Ile Val Gln Val Leu		
	225	230	235
15	Val Gln Ala Leu Leu Thr Gly Arg Ile Val Glu Trp Ile Gly Glu Ala		
	245	250	255
	Lys Thr Val Ile Ile Gly Cys Ile Thr Asp Ala Leu Gly Leu Val Gly		
	260	265	270
20	Leu Ala Ile Val Thr Asp Ala Phe Ser Met Ala Pro Ile Leu Ala Ala		
	275	280	285
	Leu Gly Ile Gly Gly Ile Gly Leu Pro Ala Leu Gln Thr Leu Leu Ser		
25	290	295	300
	Gln Arg Val Asp Glu Gln His Gln Gly Arg Leu Gln Gly Val Leu Ala		
	305	310	315
30	Ser Ile Asn Ser Val Thr Ser Ile Phe Gly Pro Val Ala Phe Thr Thr		
	325	330	335
	Ile Phe Ala Leu Thr Tyr Ile Asn Ala Asp Gly Phe Leu Trp Leu Cys		
	340	345	350
35	Ala Ala Ala Leu Tyr Val Pro Cys Val Ile Leu Ile Met Arg Gly Thr		
	355	360	365
	Ala Ala Ser Pro Lys Phe Gly Ser Trp Ala Ser Gly Asp Ser Met		
40	370	375	380
	<210> 8		
	<211> 279		
45	<212> AadA-PRT		
	<213> Corynebacterium glutamicum LP-6		
	<400> 8		
	Met Met Ser Asn Ser Ile His Thr Gly Ile Ser Arg Gln Leu Ser Gln		
50	1	5	10
	Ala Arg Asp Val Ile Lys Arg His Leu Ala Ser Thr Leu Lys Ala Ile		
	20	25	30

His Leu Tyr Gly Ser Ala Ile Asp Gly Gly Leu Lys Pro Tyr Ser Asp
 35 40 45
 5 Ile Asp Leu Leu Val Thr Val Asp Ala Arg Leu Asp Glu Ala Thr Arg
 50 55 60
 Arg Ser Leu Met Leu Asp Phe Leu Asn Ile Ser Ala Pro Pro Cys Glu
 65 70 75 80
 10 Ser Ser Ile Leu Arg Pro Leu Glu Val Thr Val Val Ala Cys Asn Glu
 85 90 95
 Val Val Pro Trp Arg Tyr Pro Ala Arg Arg Glu Leu Gln Phe Gly Glu
 100 105 110
 15 Trp Leu Arg Glu Asp Ile Leu Glu Gly Val Phe Glu Pro Ala Ala Leu
 115 120 125
 20 Asp Ala Asp Leu Ala Ile Leu Ile Thr Lys Ala Arg Gln His Ser Ile
 130 135 140
 Ala Leu Val Gly Pro Val Ala Gln Lys Val Phe Met Pro Val Pro Glu
 145 150 155 160
 25 His Asp Phe Leu Gln Val Leu Ser Asp Thr Leu Lys Leu Trp Asn Thr
 165 170 175
 30 His Glu Asp Trp Glu Asn Glu Glu Arg Asn Ile Val Leu Thr Leu Ala
 180 185 190
 Arg Ile Trp Tyr Ser Thr Glu Thr Gly Gly Ile Val Pro Lys Asp Val
 195 200 205
 35 Ala Ala Glu Trp Val Leu Glu Arg Leu Pro Ala Glu His Lys Pro Ile
 210 215 220
 Leu Val Glu Ala Arg Gln Ala Tyr Leu Gly Leu Cys Lys Asp Ser Leu
 225 230 235 240
 40 Ala Leu Arg Ala Asp Glu Thr Ser Ala Phe Ile Gly Tyr Ala Lys Ser
 245 250 255
 Ala Val Ala Asp Leu Leu Glu Lys Arg Lys Ser Gln Thr Ser His Ile
 260 265 270
 45 Cys Asp Gly Ala Lys Asn Val
 275
 50
 <210> 9
 <211> 570
 <212> DNA
 55 <213> Corynebacterium glutamicum LP-6
 <220>
 <221> CDS
 <222> (1)..(567)
 60 <223> tetR
 <400> 9
 atg gct cag aaa caa gcg cga ctc gat cgt gca gca gtc ttg cgc ggt 48

[illegible]

<400> 10
 Met Ala Gln Lys Gln Ala Arg Leu Asp Arg Ala Ala Val Leu Arg Gly
 1 5 10 15
 5 Ala Arg His Val Leu Asn Asn Thr Gly Ile Asp Gly Phe Thr Thr Arg
 20 25 30
 Ala Leu Ala Ala His Leu Arg Val Gln Gln Pro Ala Leu Tyr Trp His
 35 40 45
 10 Phe Arg Thr Lys Ala His Leu Leu Gly Ser Leu Ala Ala Asp Val Leu
 50 55 60
 Asp Arg Glu His His Ala Ser Leu Pro Glu Ser Gly Glu Arg Trp Asp
 65 70 75 80
 15 Asp Phe Leu Leu Arg Asn Ala Arg Ser Phe Arg Thr Ala Leu Leu Ala
 85 90 95
 20 Val Arg Asp Gly Ala Arg Leu His Ala Glu Phe His Arg Gln Lys Ser
 100 105 110
 Asp Gln Met Pro Ala Gly Ser Asp Ala Pro Glu Ser Gln Ile Glu Phe
 115 120 125
 25 Leu Val Ser Glu Gly Phe Ala Glu Gly Ser Ala Val Arg Ala Leu Met
 130 135 140
 Ala Ile Ser Arg Tyr Thr Val Gly Phe Val Leu Glu Glu Gln Thr Ala
 145 150 155 160
 30 Leu Asp Asn Gly Cys Glu Pro Val Asp Gln Asp Leu Asp Phe Glu Phe
 165 170 175
 35 Gly Leu Val Ala Met Val Glu Gly Leu Ala Ser Lys Arg
 180 185

WHAT IS CLAIMED IS:

1. Mutually compatible plasmids pTET3 and pCRY4, isolated from the strain of *Corynebacterium glutamicum* deposited under DSM number 5816, wherein plasmid pTET3 is characterised by
 - i) a length of ~ 27.8 kbp and the restriction map shown in Figure 1,
 - ii) a replication region comprising the nucleotide sequence shown in SEQ ID NO:1 and
 - 10 iii) an antibiotic resistance region consisting of a tetA gene imparting tetracycline resistance and an aadA gene imparting streptomycin and spectinomycin resistance, shown in SEQ ID NO:6, and plasmid pCRY4 is characterised by
- 15
 - iv) a length of ~ 48 kbp and the restriction map shown in Figure 2, and
 - v) a replication region comprising the nucleotide sequence shown in SEQ ID NO:4.
2. A composite plasmid capable of autonomous replication
 - 20 in coryneform bacteria, said plasmid comprising
 - i) at least a portion of the nucleotide sequence of plasmid pTET3 or pCRY4,
 - ii) at least one DNA replication region derived from one of the plasmids pTET3 or pCRY4,
 - 25 iii) a gene fragment which is derived from *E. coli*, *B. subtilis* or *Streptomyces* and may multiply therein, and

- iv) at least one region that expresses a protein for active substance resistance.
- 3. A composite plasmid according to claim 2,
which contains at least one region for active substance
5 resistance from plasmid pTET3.
- 4. A composite plasmid according to claim 3,
which contains at least a portion of the nucleotide
sequences of plasmids pGA1 and/or pGA2.
- 5. A composite plasmid according to claim 2,
10 which contain at least one DNA fragment which encodes a
gene from the biosynthetic pathway of a vitamin, a
nucleotide or an L-amino acid and is expressed in
coryneform bacteria.
- 6. A plasmid vector capable of autonomous replication in
15 coryneform bacteria containing
 - i) at least one DNA replication region derived from
one of the plasmids pGA1, pGA2, pTET3 or pCRY4,
 - ii) at least one active substance resistance from the
plasmid pTET3 and optionally
 - 20 iii) at least one DNA fragment which encodes a gene
from the biosynthetic pathway of a vitamin, a
nucleotide or an L-amino acid and is expressed in
coryneform bacteria.
- 7. Plasmid vector pSELF3-1, which has a length of
25 ~ 7.0 kbp and the restriction map depicted in Figure 6.
- 8. Plasmid vector pSELF1-1, which has a length of
~ 7.3 kbp and the restriction map depicted in Figure 7.

9. A process for the production of L-amino acids, by fermentation of coryneform bacteria, wherein a strain is used which contains at least one plasmid vector according to one of claims 2 to 7.
- 5 10. The process according to claim 9 wherein the L-amino acid is L-lysine or L-threonine.
11. A process for the production of a vitamin by fermentation of coryneform bacteria, wherein a strain is used which contains at least one plasmid
10 vector according to claim 7 or claim 8.
12. The process according to claim 11 wherein the vitamin is D-pantothenic acid.

**Plasmids from *Corynebacterium glutamicum* and use
thereof**

Abstract

This invention relates to the mutually compatible plasmids
5 pTET3 and pCRY4, isolated from the strain of
Corynebacterium glutamicum deposited under DSM number 5616,
wherein plasmid pTET3 is characterised by

- 1.1 a length of ~ 27.8 kbp and the restriction map
shown in Figure 1,
- 10 1.2 a replication region comprising the nucleotide
sequence shown in SEQ ID no. 1 and
- 1.3 an antibiotic resistance region consisting of a
tetA gene imparting tetracycline resistance and
an aadA gene imparting streptomycin and
15 spectinomycin resistance, shown in SEQ ID no. 6,

and plasmid pCRY4 is characterised by

- 1.4 a length of ~ 48 kbp and the restriction map
shown in Figure 2 and
- 1.5 a replication region comprising the nucleotide
20 sequence shown in SEQ ID no. 4

to composite plasmid vectors of these plasmids which are
capable of autonomous replication in coryneform bacteria
and to processes for the production of L-amino acids,
vitamins and nucleotides using these bacteria.

Figure 1:




Figure 2:






Figure 3:



5

Figure 4:



10

Figure 5:


**pTET3-DNA**

Figure 6:

5




Figure 7:

